| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | N/A | NRG Oncology | <1 mi |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | <1 mi |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | <1 mi |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Phase 3 | Sumitomo Pharma Switzerland GmbH | <1 mi |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Cardiogenic Shock Working Group Registry | — | Tufts Medical Center | <1 mi |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | <1 mi |
| Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women | N/A | Weill Medical College of Cornell University | <1 mi |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Phase 2/3 | Biogen | <1 mi |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | <1 mi |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | Phase 1 | AstraZeneca | <1 mi |
| PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing | — | M.D. Anderson Cancer Center | <1 mi |
| A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD | Phase 3 | Lipocine Inc. | <1 mi |
| Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | Phase 2/3 | NRG Oncology | <1 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study | Phase 3 | NRG Oncology | <1 mi |
| SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Phase 3 | NRG Oncology | <1 mi |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Phase 2/3 | Daiichi Sankyo | <1 mi |
| Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | <1 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | Phase 3 | NRG Oncology | <1 mi |
| QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | Phase 3 | Pfizer | <1 mi |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | Phase 3 | NRG Oncology | <1 mi |
| This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | Phase 3 | Pfizer | <1 mi |
| A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | Phase 1 | Pfizer | <1 mi |
| Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery | — | M.D. Anderson Cancer Center | <1 mi |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability | Phase 3 | NRG Oncology | <1 mi |
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | Phase 3 | Pfizer | <1 mi |
| S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Phase 3 | Inventiva Pharma | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | Phase 3 | AbbVie | <1 mi |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting | — | Bayer | <1 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | Phase 4 | Takeda | <1 mi |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Phase 3 | Takeda | <1 mi |
| A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | Phase 3 | Shanghai Henlius Biotech | <1 mi |
| ACP-204 in Adults With Alzheimer's Disease Psychosis | Phase 2/3 | ACADIA Pharmaceuticals Inc. | <1 mi |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | <1 mi |
| A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | Phase 2 | Verona Pharma plc | <1 mi |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | Phase 2 | Atossa Therapeutics, Inc. | <1 mi |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | <1 mi |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | Phase 2 | Biostar Pharma, Inc. | <1 mi |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | <1 mi |
| Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | <1 mi |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | Phase 1/2 | Phanes Therapeutics | <1 mi |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | <1 mi |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer | Phase 3 | AstraZeneca | <1 mi |
| A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | Phase 3 | Merus B.V. | <1 mi |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | <1 mi |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | <1 mi |
| A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Phase 2 | AstraZeneca | <1 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | 89bio, Inc. | <1 mi |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Phase 2 | Sparrow Pharmaceuticals | <1 mi |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Phase 3 | Viking Therapeutics, Inc. | <1 mi |
| Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients | Phase 3 | Intra-Cellular Therapies, Inc. | <1 mi |
| Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes | Phase 2 | Eli Lilly and Company | <1 mi |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Phase 3 | Boehringer Ingelheim | <1 mi |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | 89bio, Inc. | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Phase 3 | Eli Lilly and Company | <1 mi |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | N/A | LivaNova | <1 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | <1 mi |
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | Phase 2 | Upstream Bio Inc. | <1 mi |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Phase 3 | Pfizer | <1 mi |
| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | Phase 3 | AstraZeneca | <1 mi |
| Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer | Phase 3 | NRG Oncology | <1 mi |
| Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | N/A | Endogenex, Inc. | <1 mi |
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Phase 3 | Prokidney | <1 mi |
| Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity | N/A | The Methodist Hospital Research Institute | <1 mi |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Phase 2/3 | Kardigan, Inc. | <1 mi |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | Phase 2 | Sanofi | <1 mi |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | Phase 3 | AbbVie | <1 mi |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | <1 mi |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | Phase 3 | BioNTech SE | <1 mi |
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Eccogene | <1 mi |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | <1 mi |
| 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee | Phase 2 | OrthoTrophix, Inc | <1 mi |
| Fenofibrate for Prevention of DR Worsening | Phase 3 | Jaeb Center for Health Research | <1 mi |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | Phase 3 | AstraZeneca | <1 mi |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment | Phase 3 | Viatris Innovation GmbH | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Phase 3 | UCB Biopharma SRL | <1 mi |
| A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | Phase 3 | Viatris Innovation GmbH | <1 mi |
| Patient Priorities for Survivorship Care in Older Breast Cancer Survivors | Phase 2 | The University of Texas Health Science Center, Houston | <1 mi |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Phase 3 | Eli Lilly and Company | <1 mi |
| Study of GS-0151 in Participants With Rheumatoid Arthritis | Phase 1 | Gilead Sciences | <1 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | Phase 3 | Takeda | <1 mi |
| A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | Phase 2 | AstraZeneca | <1 mi |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Phase 3 | MoonLake Immunotherapeutics AG | <1 mi |
| A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | Phase 4 | GlaxoSmithKline | <1 mi |
| Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy | Phase 4 | M.D. Anderson Cancer Center | <1 mi |
| Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies | N/A | M.D. Anderson Cancer Center | <1 mi |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Phase 2/3 | IDEAYA Biosciences | <1 mi |
| Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Phase 1 | BeiGene | <1 mi |
| A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ) | Phase 1/2 | Michelle S Ludwig | <1 mi |
| SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery | Phase 1 | SURGE Therapeutics | <1 mi |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | Phase 3 | Erasca, Inc. | <1 mi |
| A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Phase 1/2 | Cyclacel Pharmaceuticals, Inc. | <1 mi |
| A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma | Phase 1/2 | Seattle Children's Hospital | <1 mi |
| Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Phase 2 | Eli Lilly and Company | <1 mi |
| A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer | Phase 1 | Boehringer Ingelheim | <1 mi |
| A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | Phase 1 | AbbVie | <1 mi |
| A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period. | Phase 2 | Genentech, Inc. | <1 mi |
| Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Opiophobia in Adults With Advanced Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 | Phase 2 | Gilead Sciences | <1 mi |
| RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | Phase 1/2 | Cabaletta Bio | <1 mi |
| A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations | Phase 1 | Quanta Therapeutics | <1 mi |
| Impact of Aminoglycosides in Hypotensive Septic Oncology Patients | — | M.D. Anderson Cancer Center | <1 mi |
| A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| OPTDR01 Feasibility for Automated Diabetic Retinopathy Detection | — | Optain Health | <1 mi |
| A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's | N/A | Compedica Inc | <1 mi |
| Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Improving Adult Protective Services Client Outcomes: A Stepped-Care Social and Mental Health Engagement Program | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| Study of GS-0272 in Participants With Rheumatoid Arthritis | Phase 1 | Gilead Sciences | <1 mi |
| Cognitive Behavioral Intervention to Reduce Procedural Anxiety Among Woman With High Risk Pregnancies With Scheduled Cesarean Deliveries | N/A | University of Colorado, Denver | <1 mi |
| Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes | — | M.D. Anderson Cancer Center | <1 mi |
| Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | Phase 3 | AstraZeneca | <1 mi |
| A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | Phase 1 | Atavistik Bio, Inc | <1 mi |
| Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications | — | M.D. Anderson Cancer Center | <1 mi |
| Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | Phase 1/2 | Eisai Inc. | <1 mi |
| Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Phase 1 | Pliant Therapeutics, Inc. | <1 mi |
| NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | Phase 1 | Dana-Farber Cancer Institute | <1 mi |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Phase 1/2 | Immunocore Ltd | <1 mi |
| Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal Lymph Node Procedures for Penile Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery | Early 1 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | Phase 1 | Auron Therapeutics, Inc. | <1 mi |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | Phase 1/2 | Astellas Pharma Global Development, Inc. | <1 mi |
| A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine | Phase 2 | Boehringer Ingelheim | <1 mi |
| HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Phase 3 | DualityBio Inc. | <1 mi |
| U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer | Phase 1 | Daiichi Sankyo | <1 mi |
| Study of Oral MRT-2359 in Selected Cancer Patients | Phase 1/2 | Monte Rosa Therapeutics, Inc | <1 mi |
| Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | Phase 1 | Baylor College of Medicine | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers | N/A | M.D. Anderson Cancer Center | <1 mi |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Phase 1/2 | Curis, Inc. | <1 mi |
| Supporting Informed Decision Making About Multi-cancer Early Detection Testing | — | M.D. Anderson Cancer Center | <1 mi |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Phase 1 | AbbVie | <1 mi |
| Developing a Culturally Relevant Supportive Care Program for Black Patients Dealing With Advanced Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) | Phase 3 | Endo Pharmaceuticals | <1 mi |
| A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | <1 mi |
| SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | Phase 3 | Palvella Therapeutics, Inc. | <1 mi |
| Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | Phase 1 | Institut de Recherches Internationales Servier | <1 mi |
| NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Phase 1/2 | Shanghai Huaota Biopharmaceutical Co., Ltd. | <1 mi |
| Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | Phase 1 | Baylor College of Medicine | <1 mi |
| Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) | — | University of Southern California | <1 mi |
| RESPONDER-HF Trial | N/A | Corvia Medical | <1 mi |
| ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System | N/A | Edwards Lifesciences | <1 mi |
| A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | Phase 4 | Janssen Research & Development, LLC | <1 mi |
| Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease. | N/A | Nora Vanegas | <1 mi |
| Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | Phase 2 | Sanofi | <1 mi |
| Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. | Phase 1/2 | RayzeBio, Inc. | <1 mi |
| An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | Phase 2 | AstraZeneca | <1 mi |
| A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC | Phase 1/2 | AstraZeneca | <1 mi |
| Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | Phase 1 | Boehringer Ingelheim | <1 mi |
| REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | Phase 3 | Taiho Oncology, Inc. | <1 mi |
| A Study of DF6002 Alone and in Combination With Nivolumab | Phase 1 | Dragonfly Therapeutics | <1 mi |
| Study of DF1001 in Patients with Advanced Solid Tumors | Phase 1/2 | Dragonfly Therapeutics | <1 mi |
| A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | Phase 1 | Bio-Path Holdings, Inc. | <1 mi |
| Intent of Surgery for IPMN | — | NYU Langone Health | <1 mi |
| Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | Phase 1/2 | BeOne Medicines | <1 mi |
| Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | Phase 3 | AstraZeneca | <1 mi |
| AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. | Phase 1/2 | AstraZeneca | <1 mi |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | <1 mi |
| A Phase 1 Study of IM-1021 in Participants With Advanced Cancer | Phase 1 | Immunome, Inc. | <1 mi |
| Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Phase 1 | Bio-Path Holdings, Inc. | <1 mi |
| Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | <1 mi |
| Long-Term Follow-Up of Recipient of Gene Transfer Research | — | M.D. Anderson Cancer Center | <1 mi |
| A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer | Phase 1 | SOTIO Biotech AG | <1 mi |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | <1 mi |
| Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals | Phase 2 | Fred Hutchinson Cancer Center | <1 mi |
| Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™ | — | Proteocyte Diagnostics Inc. | <1 mi |
| Studying Health Outcomes After Treatment in Patients With Retinoblastoma | — | Vanderbilt-Ingram Cancer Center | <1 mi |
| A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | Phase 1 | BlossomHill Therapeutics | <1 mi |
| Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women | N/A | M.D. Anderson Cancer Center | <1 mi |
| Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer | Phase 1/2 | The Methodist Hospital Research Institute | <1 mi |
| A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors | Phase 2 | EpicentRx, Inc. | <1 mi |
| Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Revumenib and Mezigdomide in People With Leukemia | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Phase 1/2 | Children's Oncology Group | <1 mi |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | <1 mi |
| Precision Optical Guidance for Oral Biopsy | N/A | M.D. Anderson Cancer Center | <1 mi |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | Phase 3 | Celgene | <1 mi |
| A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Incyte Corporation | <1 mi |
| 18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers | — | M.D. Anderson Cancer Center | <1 mi |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | Phase 3 | Advenchen Laboratories, LLC | <1 mi |
| Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma | Phase 1/2 | Remix Therapeutics | <1 mi |
| Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Phase 2 | Academic and Community Cancer Research United | <1 mi |
| Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | Phase 4 | Novartis Pharmaceuticals | <1 mi |
| FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Fusion Pharmaceuticals Inc. | <1 mi |
| A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment | Phase 1 | Servier Bio-Innovation LLC | <1 mi |
| Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen | Phase 1 | Baylor College of Medicine | <1 mi |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Phase 1 | ImmunoGenesis | <1 mi |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | Phase 1/2 | Jazz Pharmaceuticals | <1 mi |
| A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | Phase 1/2 | D3 Bio (Wuxi) Co., Ltd | <1 mi |
| A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer | Phase 1 | Outpace Bio, Inc. | <1 mi |
| Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | — | Children's Hospital Medical Center, Cincinnati | <1 mi |
| Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer | Phase 1/2 | University of Chicago | <1 mi |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | Phase 2 | Gilead Sciences | <1 mi |
| Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | <1 mi |
| Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study of Olutasidenib and Temozolomide in HGG | Phase 2 | Rigel Pharmaceuticals | <1 mi |
| A Study of HS-20110 in Participants With Advanced Solid Tumors | Phase 1 | Hansoh BioMedical R&D Company | <1 mi |
| Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain | — | M.D. Anderson Cancer Center | <1 mi |
| TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer | Phase 2 | Children's Hospital of Philadelphia | <1 mi |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Phase 3 | European Myeloma Network B.V. | <1 mi |
| Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. | Phase 1 | Huda Salman | <1 mi |
| TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention | N/A | University Medical Center Nijmegen | <1 mi |
| Telephone Support in Advanced Gastrointestinal Cancer | N/A | Indiana University | <1 mi |
| Study of REM-422 in Patients With AML or Higher Risk MDS | Phase 1 | Remix Therapeutics | <1 mi |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) | Phase 3 | PharmaMar | <1 mi |
| Utilization of a Peer-Based Approach for the Promotion of Physical Activity in Inactive Women | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women | — | M.D. Anderson Cancer Center | <1 mi |
| KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | Phase 2/3 | Kyverna Therapeutics | <1 mi |
| A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data | — | N-Power Medicine | <1 mi |
| A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed | Phase 1/2 | GlaxoSmithKline | <1 mi |
| Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program | — | M.D. Anderson Cancer Center | <1 mi |
| A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma | N/A | M.D. Anderson Cancer Center | <1 mi |
| Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission | Phase 2 | Daiichi Sankyo | <1 mi |
| First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Phase 1/2 | Daiichi Sankyo | <1 mi |
| Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | Phase 1 | Ono Pharmaceutical Co. Ltd | <1 mi |
| Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | Phase 2/3 | BicycleTx Limited | <1 mi |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Phase 2/3 | Celgene | <1 mi |
| HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes | — | M.D. Anderson Cancer Center | <1 mi |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Phase 2 | Daiichi Sankyo | <1 mi |
| HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | Phase 1/2 | The Methodist Hospital Research Institute | <1 mi |
| CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Understanding Patient Experience Among Asians at MD Anderson | — | M.D. Anderson Cancer Center | <1 mi |
| GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma | Phase 1 | Baylor College of Medicine | <1 mi |
| Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas | — | University of Michigan Rogel Cancer Center | <1 mi |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | Phase 1/2 | Adagene Inc | <1 mi |
| Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies | Phase 1/2 | Replimune Inc. | <1 mi |
| A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | Phase 1/2 | Debiopharm International SA | <1 mi |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Phase 1/2 | enGene, Inc. | <1 mi |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Karyopharm Therapeutics Inc | <1 mi |
| Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" | N/A | M.D. Anderson Cancer Center | <1 mi |
| Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer | Phase 1/2 | BioNTech SE | <1 mi |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy | N/A | Medical University of South Carolina | <1 mi |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Phase 2 | Cogent Biosciences, Inc. | <1 mi |
| Neuroblastoma Maintenance Therapy Trial | Phase 2 | Giselle Sholler | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | Phase 2 | Telios Pharma, Inc. | <1 mi |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | Phase 1/2 | Immatics US, Inc. | <1 mi |
| Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | Phase 3 | Philogen S.p.A. | <1 mi |
| A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Expressive Writing for the Management of Stress in Cancer Survivors | N/A | M.D. Anderson Cancer Center | <1 mi |
| Simple Bone Cysts in Kids | Phase 3 | The Hospital for Sick Children | <1 mi |
| Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment | Phase 1 | Taiho Oncology, Inc. | <1 mi |
| Development of an Educational Patient Decision Aid (Treatments in Advanced Cancer - Decision Aid, TA-DA) to Promote Shared Decision Making for Third-line or Beyond Palliative Systemic Therapy | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study of PHST001 in Advanced Solid Tumors | Phase 1 | Pheast Therapeutics | <1 mi |
| Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors | — | National Cancer Institute (NCI) | <1 mi |
| CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Phase 1 | Cullinan Therapeutics Inc. | <1 mi |
| A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | OnCusp Therapeutics, Inc. | <1 mi |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors | Phase 1 | DualityBio Inc. | <1 mi |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Phase 2 | CG Oncology, Inc. | <1 mi |
| A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | Phase 3 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations | Phase 1 | Adlai Nortye Biopharma Co., Ltd. | <1 mi |
| A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 | Dana-Farber Cancer Institute | <1 mi |
| Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Spanish Decision Tool for Ovarian Cancer Maintenance Therapy | N/A | M.D. Anderson Cancer Center | <1 mi |
| Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | Phase 1/2 | Heidelberg Pharma AG | <1 mi |
| Anti-GD2 ADC M3554 in Advanced Solid Tumors | Phase 1 | EMD Serono Research & Development Institute, Inc. | <1 mi |
| Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma | Phase 1 | Baylor College of Medicine | <1 mi |
| A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | Phase 4 | Eli Lilly and Company | <1 mi |
| Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors | Phase 1 | OncoC4, Inc. | <1 mi |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | Phase 3 | Verrica Pharmaceuticals Inc. | <1 mi |
| A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | Phase 2 | Children's Oncology Group | <1 mi |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Phase 3 | IDEAYA Biosciences | <1 mi |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | Phase 1/2 | Crinetics Pharmaceuticals Inc. | <1 mi |
| Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease | Early 1 | M.D. Anderson Cancer Center | <1 mi |
| Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | Phase 1/2 | Recursion Pharmaceuticals Inc. | <1 mi |
| A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | Phase 3 | Kite, A Gilead Company | <1 mi |
| New Assessment System in Measuring Symptom Distress in Cancer Patients | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients | Phase 3 | Children's Oncology Group | <1 mi |
| Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | Phase 3 | Vor Biopharma | <1 mi |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL | Phase 3 | Acrotech Biopharma Inc. | <1 mi |
| Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow | Phase 2 | Y-mAbs Therapeutics | <1 mi |
| A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors | — | M.D. Anderson Cancer Center | <1 mi |
| PrehabPal: A Digital Tool to Help Older Adults Prepare for Cancer Surgery | N/A | University of California, San Francisco | <1 mi |
| A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | Phase 1 | Orca Biosystems, Inc. | <1 mi |
| DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | Phase 2 | Diakonos Oncology Corporation | <1 mi |
| Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer | — | Mayo Clinic | <1 mi |
| Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma | N/A | Melanoma and Skin Cancer Trials Limited | <1 mi |
| Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery | Phase 2 | The Methodist Hospital Research Institute | <1 mi |
| Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | Phase 1 | City of Hope Medical Center | <1 mi |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer | Phase 2/3 | Oncotelic Inc. | <1 mi |
| Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | Phase 3 | Servier Bio-Innovation LLC | <1 mi |
| Actinium Therapy for Late-stage Aggressive Sarcomas | Phase 1 | Ratio Therapeutics, Inc. | <1 mi |
| Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Phase 1/2 | Artios Pharma Ltd | <1 mi |
| C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | Phase 1 | Baylor College of Medicine | <1 mi |
| Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer | Phase 2 | Baylor College of Medicine | <1 mi |
| Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma | — | Australia and New Zealand Sarcoma Association | <1 mi |
| A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | Phase 2 | BioNTech SE | <1 mi |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | N/A | University of Colorado, Denver | <1 mi |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | — | Children's Oncology Group | <1 mi |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Phase 3 | PedAL BCU, LLC | <1 mi |
| A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | <1 mi |
| Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | <1 mi |
| Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas | Early 1 | M.D. Anderson Cancer Center | <1 mi |
| A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Sanofi | <1 mi |
| Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia | Phase 1 | Shenzhen TargetRx Co., Ltd. | <1 mi |
| Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | Phase 1/2 | Children's Oncology Group | <1 mi |
| P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma | Phase 1 | Poseida Therapeutics, Inc. | <1 mi |
| Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Amgen | <1 mi |
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | Phase 2 | Massachusetts General Hospital | <1 mi |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma | Phase 1 | Diakonos Oncology Corporation | <1 mi |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | Phase 1/2 | Shanghai EpimAb Biotherapeutics Co., Ltd. | <1 mi |
| Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial | Phase 3 | NRG Oncology | <1 mi |
| Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression | Phase 1/2 | AstraZeneca | <1 mi |
| Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | Phase 1 | Incyte Corporation | <1 mi |
| Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance | — | M.D. Anderson Cancer Center | <1 mi |
| A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer | Phase 3 | AbbVie | <1 mi |
| Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Phase 3 | AstraZeneca | <1 mi |
| A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | <1 mi |
| A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | — | City of Hope Medical Center | <1 mi |
| Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers | N/A | M.D. Anderson Cancer Center | <1 mi |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL | Phase 3 | Soligenix | <1 mi |
| A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Avistone Biotechnology Co., Ltd. | <1 mi |
| A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| EUS-RFA PANCARDINAL-1 Trial | Phase 2 | The University of Texas Health Science Center, Houston | <1 mi |
| Study of APR-1051 in Patients With Advanced Solid Tumors | Phase 1 | Aprea Therapeutics | <1 mi |
| Childhood Cancer Predisposition Study (CCPS) | — | Emory University | <1 mi |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | Phase 1 | Caribou Biosciences, Inc. | <1 mi |
| First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Phase 1 | Therapeutic Advances in Childhood Leukemia Consortium | <1 mi |
| A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Trial of Ixazomib for Kaposi Sarcoma | Phase 2 | AIDS Malignancy Consortium | <1 mi |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 3 | Celgene | <1 mi |
| Prospective Study to Assess a Diagnostic Aid for Cancer | — | Harbinger Health | <1 mi |
| Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors | Phase 1 | Adcentrx Therapeutics | <1 mi |
| An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of BG-C477 in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1/2 | AB Science | <1 mi |
| To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation | Phase 2 | Abion Inc | <1 mi |
| Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | Phase 3 | NRG Oncology | <1 mi |
| Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | Early 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy | Phase 2 | Stemline Therapeutics, Inc. | <1 mi |
| A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma | Phase 1/2 | AstraZeneca | <1 mi |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Phase 1 | ArriVent BioPharma, Inc. | <1 mi |
| Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant | Phase 1/2 | SNIPR Biome Aps. | <1 mi |
| A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass | — | Cleo Diagnostics Ltd | <1 mi |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Phase 1 | Inhibrx Biosciences, Inc | <1 mi |
| A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Erasca, Inc. | <1 mi |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Phase 3 | Lyell Immunopharma, Inc. | <1 mi |
| Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors | Phase 1 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | <1 mi |
| A Study of ZL-1310 in Participants With Selected Solid Tumors | Phase 1/2 | Zai Lab (Shanghai) Co., Ltd. | <1 mi |
| Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients | — | M.D. Anderson Cancer Center | <1 mi |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | Phase 2 | Astellas Pharma Global Development, Inc. | <1 mi |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | Phase 1/2 | Daiichi Sankyo | <1 mi |
| Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | Phase 2/3 | M.D. Anderson Cancer Center | <1 mi |
| Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Study in Advanced Solid Tumor Patients | Phase 1/2 | Callio Therapeutics | <1 mi |
| Screening Women With Prior HPV for Anal Neoplasia | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Phase 1 | Children's Oncology Group | <1 mi |
| Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | Phase 1/2 | Cellectis S.A. | <1 mi |
| A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma | — | Aura Biosciences | <1 mi |
| The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | <1 mi |
| Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | Phase 1/2 | Susan Chi, MD | <1 mi |
| Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Metastatic Leiomyosarcoma Biomarker Protocol | — | University of Michigan Rogel Cancer Center | <1 mi |
| Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | <1 mi |
| A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Phase I Study of HC-7366 for Acute Myeloid Leukemia | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies | — | M.D. Anderson Cancer Center | <1 mi |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Phase 2 | Hoffmann-La Roche | <1 mi |
| A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Exelixis | <1 mi |
| A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors | Phase 1 | Nested Therapeutics, Inc | <1 mi |
| A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Imugene Limited | <1 mi |
| Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Sacral Neuromodulation for Male Overactive Bladder (MOAB) | N/A | Axonics, Inc. | <1 mi |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer | Phase 1 | Akamis Bio | <1 mi |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| PM14 Administered Intravenously to Patients with Advanced Solid Tumors | Phase 1 | PharmaMar | <1 mi |
| A Virtual, Group-Based, Expressive Writing Intervention for Survivors of Adolescent and Young Adult Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization | — | M.D. Anderson Cancer Center | <1 mi |
| Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors | Phase 1 | Acrivon Therapeutics | <1 mi |
| A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma | — | M.D. Anderson Cancer Center | <1 mi |
| A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. | Phase 1/2 | AstraZeneca | <1 mi |
| A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma | N/A | Alpha Tau Medical LTD. | <1 mi |
| Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment | — | Daiichi Sankyo | <1 mi |
| Primary Tumor Research and Outcomes Network | — | AO Innovation Translation Center | <1 mi |
| Asciminib Roll-over Study | Phase 4 | Novartis Pharmaceuticals | <1 mi |
| Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer | Phase 1 | The Methodist Hospital Research Institute | <1 mi |
| Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors | Phase 1 | Debiopharm International SA | <1 mi |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | <1 mi |
| A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis | Phase 1/2 | ImmunAbs Inc. | <1 mi |
| Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia | Phase 1 | Pacylex Pharmaceuticals | <1 mi |
| A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population | Phase 2 | Baylor College of Medicine | <1 mi |
| TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Phase 2 | American Society of Clinical Oncology | <1 mi |
| Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma | Phase 1 | Neomorph, Inc | <1 mi |
| A Phase 1 Study of NM6603 in Advanced Solid Tumors | Phase 1 | NucMito Pharmaceuticals Co. Ltd. | <1 mi |
| Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | Phase 1 | Boehringer Ingelheim | <1 mi |
| Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Phase 3 | Daiichi Sankyo | <1 mi |
| A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Krystal Biotech, Inc. | <1 mi |
| Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer | Phase 2 | The Methodist Hospital Research Institute | <1 mi |
| A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1/2 | Halda Therapeutics OpCo, Inc. | <1 mi |
| Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| ACTengine® IMA203 Combined With mRNA-4203 | Phase 1 | Immatics US, Inc. | <1 mi |
| BOLSTER: Learning New Skills to Thrive | N/A | Dana-Farber Cancer Institute | <1 mi |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Phase 2/3 | Global Coalition for Adaptive Research | <1 mi |
| Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment. | — | M.D. Anderson Cancer Center | <1 mi |
| AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Phase 1 | Carna Biosciences, Inc. | <1 mi |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | <1 mi |
| Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique | N/A | M.D. Anderson Cancer Center | <1 mi |
| Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors | Phase 1 | Tagworks Pharmaceuticals BV | <1 mi |
| A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study | N/A | M.D. Anderson Cancer Center | <1 mi |
| Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions | — | Ohio State University Comprehensive Cancer Center | <1 mi |
| Molecular Epidemiology of Biliary Tree Cancers | — | M.D. Anderson Cancer Center | <1 mi |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | Phase 3 | Polaris Group | <1 mi |
| Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | — | Alexion Pharmaceuticals, Inc. | <1 mi |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | <1 mi |
| Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 | Phase 2 | Ebrahim S Delpassand | <1 mi |
| Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Phase 1/2 | Juno Therapeutics, a Subsidiary of Celgene | <1 mi |
| A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | Phase 1/2 | Pfizer | <1 mi |
| Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies | N/A | University of Colorado, Denver | <1 mi |
| VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | Phase 1/2 | University of Texas Southwestern Medical Center | <1 mi |
| Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 3 | GOG Foundation | <1 mi |
| ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Phase 2 | Nationwide Children's Hospital | <1 mi |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | <1 mi |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | <1 mi |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | <1 mi |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | Phase 1/2 | Vironexis Biotherapeutics Inc. | <1 mi |
| A Study of PYX-201 in Advanced Solid Tumors | Phase 1 | Pyxis Oncology, Inc | <1 mi |
| 18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors | Phase 1 | MediLink Therapeutics (Suzhou) Co., Ltd. | <1 mi |
| Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Development of Brief Positive Affect Treatment (PAT) for Caregivers of Patients With Advanced Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | <1 mi |
| A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Phase 1 | Kura Oncology, Inc. | <1 mi |
| Target Muscle Re-innervation and Regenerative Peripheral Nerve Interfaces Alone and in Combination for the Treatment of Residual and Phantom Limb Pain in Cancer Patients Who Have Received an Amputation | N/A | M.D. Anderson Cancer Center | <1 mi |
| CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) | Phase 1 | Baylor College of Medicine | <1 mi |
| A Study of DM002 in Patients With Advanced Solid Tumors | Phase 1 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | <1 mi |
| TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. | Phase 1 | Baylor College of Medicine | <1 mi |
| HPV Vaccine, Imiquimod, and Metformin Combination Trial | Phase 2 | Baylor College of Medicine | <1 mi |
| Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Phase 1/2 | Merus B.V. | <1 mi |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | Genmab | <1 mi |
| A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | Phase 2 | AbbVie | <1 mi |
| Distribution of Lymph Node Metastases in Esophageal Carcinoma | — | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | <1 mi |
| A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body | — | Bayer | <1 mi |
| Survey of Current Interventional and Diagnostic Imaging Residents After Participation in Endovascular Simulator Training | — | M.D. Anderson Cancer Center | <1 mi |
| Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) | Phase 2 | Frantz Viral Therapeutics, LLC | <1 mi |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | <1 mi |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) | Phase 1 | AstraZeneca | <1 mi |
| A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | Phase 1 | Arvinas Inc. | <1 mi |
| A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Phase 1 | Edgewood Oncology Inc. | <1 mi |
| A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | Phase 1 | Nectin Therapeutics Ltd | <1 mi |
| Implementation and Evaluation of an Evidence-Based, Multilevel Lifestyle Intervention for Underserved and Rural Populations in South Texas | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes | Phase 1 | Remedy Plan, Inc. | <1 mi |
| Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML | Phase 1 | Montefiore Medical Center | <1 mi |
| Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL | Phase 1/2 | Dana-Farber Cancer Institute | <1 mi |
| Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) | N/A | National Cancer Institute (NCI) | <1 mi |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | <1 mi |
| Validation of the Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) Tool for Use in a Physical Medicine Rehabilitation Clinic | — | M.D. Anderson Cancer Center | <1 mi |
| Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Quality of Life and Function of Patients With Pelvic Tumors After Undergoing Hemipelvectomy | — | M.D. Anderson Cancer Center | <1 mi |
| Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| CD4CAR for CD4+ Leukemia and Lymphoma | Phase 1 | Huda Salman | <1 mi |
| A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Phase 1/2 | Nuvalent Inc. | <1 mi |
| Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies | Phase 1 | Epigenetix, Inc. | <1 mi |
| A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) | Phase 3 | AstraZeneca | <1 mi |
| Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Parabilis Medicines, Inc. | <1 mi |
| A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | Phase 1 | Flare Therapeutics Inc. | <1 mi |
| Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer | Phase 2 | Martha Mims | <1 mi |
| CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Phase 1 | Cullinan Therapeutics Inc. | <1 mi |
| A Study of YL201 in Patients With Advanced Solid Tumors | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | <1 mi |
| A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) | Phase 1/2 | Terns, Inc. | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan | Phase 2 | AbbVie | <1 mi |
| Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Pancreatic Cancer Early Detection Consortium | — | Arbor Research Collaborative for Health | <1 mi |
| Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | Phase 1 | Baylor College of Medicine | <1 mi |
| Validation of Pre-clinical Nano-Based Analgesics in Cells From Human Dorsal Root Ganglia | — | M.D. Anderson Cancer Center | <1 mi |
| Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | Phase 1/2 | Effector Therapeutics | <1 mi |
| International Registry for Men With Advanced Prostate Cancer (IRONMAN) | — | Prostate Cancer Clinical Trials Consortium | <1 mi |
| A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Phase 1/2 | Takeda | <1 mi |
| PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | PanTher Therapeutics | <1 mi |
| A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | Phase 1/2 | ImmunoGenesis | <1 mi |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Molecular Genetics Studies of Cancer Patients and Their Relatives | — | City of Hope Medical Center | <1 mi |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | Phase 2 | SWOG Cancer Research Network | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease | Phase 2 | AbbVie | <1 mi |
| A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Phase 3 | Corvus Pharmaceuticals, Inc. | <1 mi |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems | N/A | M.D. Anderson Cancer Center | <1 mi |
| Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis | Phase 3 | Rapamycin Holdings Inc. | <1 mi |
| Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies | — | M.D. Anderson Cancer Center | <1 mi |
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | Phase 2 | Roswell Park Cancer Institute | <1 mi |
| A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. | Phase 1/2 | Xerient Pharma | <1 mi |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | <1 mi |
| Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer | Phase 3 | University of Utah | <1 mi |
| Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | Phase 4 | Eli Lilly and Company | <1 mi |
| Effect of Photobiomodulation on Pain and Healing of the Vertical Releasing Incision After Endodontic Microsurgery | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC). | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | <1 mi |
| UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML | Early 1 | Joanna Yi | <1 mi |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Phase 3 | Nuvation Bio Inc. | <1 mi |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Phase 3 | Karyopharm Therapeutics Inc | <1 mi |
| Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study of CTD402 in T-ALL/LBL Patients | Phase 1/2 | BIOHENG THERAPEUTICS US LLC | <1 mi |
| A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer | Phase 3 | Astellas Pharma Global Development, Inc. | <1 mi |
| Testing eSCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents of Children With Cancer | N/A | Nemours Children's Clinic | <1 mi |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Phase 1 | Jazz Pharmaceuticals | <1 mi |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Phase 1 | Bristol-Myers Squibb | <1 mi |
| A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) | Phase 1/2 | Debiopharm International SA | <1 mi |
| Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies | — | M.D. Anderson Cancer Center | <1 mi |
| A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | Phase 1 | Fate Therapeutics | <1 mi |
| Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer | Phase 1/2 | Shenzhen Ionova Life Sciences Co., Ltd. | <1 mi |
| ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas | Phase 2 | Nationwide Children's Hospital | <1 mi |
| Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | — | M.D. Anderson Cancer Center | <1 mi |
| First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Bayer | <1 mi |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Phase 3 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | Phase 1/2 | Sellas Life Sciences Group | <1 mi |
| A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1/2 | Celgene | <1 mi |
| Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix | — | M.D. Anderson Cancer Center | <1 mi |
| Perceptions of Hospital Care at Home for Patients With Cancer: A Qualitative Study of Cancer Providers, Patients and Caregivers. | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors | Phase 1 | BridGene Biosciences Inc. | <1 mi |
| A Study of 177Lu-FAP-2286 in Advanced Solid Tumors | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) | Phase 2 | Wugen, Inc. | <1 mi |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Digital Art Activity to Enhance Self-Disclosure and the Detection of Psycho-social Distress in Adult Cancer Patients | — | M.D. Anderson Cancer Center | <1 mi |
| A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 | Phase 1/2 | Pathos AI, Inc. | <1 mi |
| Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors | Phase 1 | Virogin Biotech Canada Ltd | <1 mi |
| Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab | N/A | Pack Health | <1 mi |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | Phase 2/3 | Novartis Pharmaceuticals | <1 mi |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Phase 1/2 | Tanja Andrea Gruber | <1 mi |
| A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | Erasca, Inc. | <1 mi |
| A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Phase 1/2 | ImmunityBio, Inc. | <1 mi |
| A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors | Phase 1 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Phase 3 | Incyte Corporation | <1 mi |
| Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 | Phase 1 | SystImmune Inc. | <1 mi |
| A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | Phase 1 | Chugai Pharmaceutical | <1 mi |
| Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors | Phase 1 | Gilead Sciences | <1 mi |
| Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas | Phase 1 | Baylor College of Medicine | <1 mi |
| A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) | Phase 1 | Boehringer Ingelheim | <1 mi |
| Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment | Phase 1 | Taiho Oncology, Inc. | <1 mi |
| Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions | — | M.D. Anderson Cancer Center | <1 mi |
| A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation | Phase 2 | Amgen | <1 mi |
| Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours | Phase 1/2 | Ipsen | <1 mi |
| Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | <1 mi |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | Phase 1/2 | St. Jude Children's Research Hospital | <1 mi |
| A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study | — | Mayo Clinic | <1 mi |
| A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Phase 1 | Jazz Pharmaceuticals | <1 mi |
| Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Nerviano Medical Sciences | <1 mi |
| MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas | N/A | M.D. Anderson Cancer Center | <1 mi |
| Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | Phase 1/2 | Jiangsu HengRui Medicine Co., Ltd. | <1 mi |
| A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | Phase 1/2 | Amgen | <1 mi |
| Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial | N/A | Palette Life Sciences, Inc. | <1 mi |
| Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) | Phase 1 | Rgenta Therapeutics Inc | <1 mi |
| A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | MOMA Therapeutics | <1 mi |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Phase 2/3 | Bicara Therapeutics | <1 mi |
| Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors | Phase 1 | Exelixis | <1 mi |
| UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies | Phase 1 | Ubix Therapeutics, Inc. | <1 mi |
| Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy | Phase 2 | Spectrum Pharmaceuticals, Inc | <1 mi |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Personalized NK Cell Therapy in CBT | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Pan Tumor Rollover Study | Phase 2 | Bristol-Myers Squibb | <1 mi |
| Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors | Phase 1 | InSilico Medicine Hong Kong Limited | <1 mi |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | Phase 1 | Hoffmann-La Roche | <1 mi |
| A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| Traction vs. No Traction in Colonic ESD | N/A | Baylor College of Medicine | <1 mi |
| A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1) | Phase 1/2 | Anaveon AG | <1 mi |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Phase 3 | Immatics US, Inc. | <1 mi |
| Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers | — | M.D. Anderson Cancer Center | <1 mi |
| Decoupling Immunotherapy Toxicity and Cancer Response | — | M.D. Anderson Cancer Center | <1 mi |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Phase 2/3 | Blueprint Medicines Corporation | <1 mi |
| A Study of Lorigerlimab in Participants With Advanced Solid Tumors | Phase 2 | MacroGenics | <1 mi |
| Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers | Phase 2/3 | M.D. Anderson Cancer Center | <1 mi |
| Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | Phase 3 | Amgen | <1 mi |
| Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management | — | M.D. Anderson Cancer Center | <1 mi |
| A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | Phase 2 | Disc Medicine, Inc | <1 mi |
| EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | Phase 1 | Aura Biosciences | <1 mi |
| EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | Phase 1/2 | Eisbach Bio GmbH | <1 mi |
| A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Hoffmann-La Roche | <1 mi |
| Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors | Phase 1/2 | OncoC4, Inc. | <1 mi |
| iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | Phase 1 | AbbVie | <1 mi |
| Trial of DFP-14927 in Advanced Solid Tumors | Phase 1 | Delta-Fly Pharma, Inc. | <1 mi |
| Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| The Cancer Stage Shifting Initiative: Registry and Biorepository to Research and Address Health Disparities in Cancer Care | — | National Minority Quality Forum | <1 mi |
| SLV-324 Treatment of Metastatic Solid Tumors | Phase 1 | Solve Therapeutics | <1 mi |
| A Study of ZN-c3 in Patients With Ovarian Cancer | Phase 1 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | <1 mi |
| Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion | Early 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Phase 3 | Loxo Oncology, Inc. | <1 mi |
| A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers | — | M.D. Anderson Cancer Center | <1 mi |
| ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | Phase 1 | Adcendo ApS | <1 mi |
| Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy | — | Massachusetts General Hospital | <1 mi |
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | Phase 3 | Cartesian Therapeutics | <1 mi |
| Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery | N/A | University Health Network, Toronto | <1 mi |
| A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation | Phase 1 | TScan Therapeutics, Inc. | <1 mi |
| Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma | Phase 1 | Baylor College of Medicine | <1 mi |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | Phase 2 | St. Jude Children's Research Hospital | <1 mi |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Phase 3 | Kura Oncology, Inc. | <1 mi |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | <1 mi |
| A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation | Phase 2 | Center for International Blood and Marrow Transplant Research | <1 mi |
| Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening | N/A | M.D. Anderson Cancer Center | <1 mi |
| Clinical and Molecular Features of Oral Premalignancy and Oral Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | Phase 1/2 | BeOne Medicines | <1 mi |
| Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection | N/A | Baylor College of Medicine | <1 mi |
| Self-sampling to Optimize Anal Lesion Outcomes | N/A | Medical College of Wisconsin | <1 mi |
| Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery | N/A | M.D. Anderson Cancer Center | <1 mi |
| Childhood Cancer Survivor Study | — | St. Jude Children's Research Hospital | <1 mi |
| Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 2 | Tyra Biosciences, Inc | <1 mi |
| Adoptive Cell Therapy Long-term Follow-up (LTFU) Study | Phase 1 | USWM CT, LLC | <1 mi |
| Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | Phase 1/2 | AstraZeneca | <1 mi |
| Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis | N/A | M.D. Anderson Cancer Center | <1 mi |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | Phase 1/2 | Curis, Inc. | <1 mi |
| Development and Pilot Trial of Focused ACT (FACT) for Patients With Advanced Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Phase 1/2 | Syndax Pharmaceuticals | <1 mi |
| A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | Phase 3 | AVEO Pharmaceuticals, Inc. | <1 mi |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | Phase 1 | Vividion Therapeutics, Inc. | <1 mi |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor | Phase 1 | Abbisko Therapeutics Co, Ltd | <1 mi |
| Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE | Phase 1 | Baylor College of Medicine | <1 mi |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | Phase 2 | Children's Oncology Group | <1 mi |
| Systematic Light Exposure in Pediatric Brain Tumor Survivors | N/A | Baylor College of Medicine | <1 mi |
| Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy | N/A | University of Virginia | <1 mi |
| ORB-021 In Patients With Advanced Solid Tumors | Phase 1 | Orionis Biosciences Inc | <1 mi |
| Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study) | N/A | M.D. Anderson Cancer Center | <1 mi |
| Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia | Phase 1/2 | AstraZeneca | <1 mi |
| Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera | Phase 3 | Italfarmaco | <1 mi |
| A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes | Phase 1/2 | Chordia Therapeutics, Inc. | <1 mi |
| Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Phase 2 | AstraZeneca | <1 mi |
| Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer | N/A | Anthony Costales, MD | <1 mi |
| Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML | Phase 1 | Stelexis BioSciences | <1 mi |
| A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes | — | M.D. Anderson Cancer Center | <1 mi |
| First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies | Phase 1/2 | VelaVigo Bio Inc | <1 mi |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Together Stronger: A Family-centered Lifestyle Intervention for Black Prostate Cancer Survivors and Their Caregivers | N/A | M.D. Anderson Cancer Center | <1 mi |
| Targeted Therapy to Increase RAI Uptake in Metastatic DTC | — | Children's Hospital of Philadelphia | <1 mi |
| QTX3034 in Patients With KRAS G12D Mutation | Phase 1 | Quanta Therapeutics | <1 mi |
| Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study | N/A | M.D. Anderson Cancer Center | <1 mi |
| Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | Phase 1 | Acepodia Biotech, Inc. | <1 mi |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | Phase 3 | Genelux Corporation | <1 mi |
| A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia | Phase 2 | MeiraGTx, LLC | <1 mi |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions | — | Baylor College of Medicine | <1 mi |
| A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Cultural Tailoring and Pilot Testing of an Inpatient Yoga Therapy Program for Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation in India, Tanzania, and the United States | N/A | M.D. Anderson Cancer Center | <1 mi |
| Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma | Phase 1/2 | Baylor College of Medicine | <1 mi |
| Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Phase 1/2 | Sumitomo Pharma America, Inc. | <1 mi |
| Shield Post-Approval Study Protocol | — | Guardant Health, Inc. | <1 mi |
| Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies | — | M.D. Anderson Cancer Center | <1 mi |
| A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | Phase 3 | NovoCure GmbH | <1 mi |
| Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Phase 3 | Day One Biopharmaceuticals, Inc. | <1 mi |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations | Phase 2 | Boehringer Ingelheim | <1 mi |
| Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma | Phase 1/2 | Genfit | <1 mi |
| Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma | — | M.D. Anderson Cancer Center | <1 mi |
| A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors | Phase 1/2 | Crossignal Therapeutics, Inc. | <1 mi |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | <1 mi |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | Phase 1/2 | Indapta Therapeutics, INC. | <1 mi |
| A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | Phase 1 | Celgene | <1 mi |
| A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | Phase 1 | Syndax Pharmaceuticals | <1 mi |
| Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Role of Diet on the Microbiome of the Digestive System | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | Phase 1 | Antengene Biologics Limited | <1 mi |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma | Early 1 | M.D. Anderson Cancer Center | <1 mi |
| Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease | — | M.D. Anderson Cancer Center | <1 mi |
| Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy | N/A | JSR Medical Co., Ltd. | <1 mi |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s) | Phase 1 | Hoffmann-La Roche | <1 mi |
| BTM-3566 in Advanced Solid Tumors | Phase 1 | Bantam Pharmaceuticals | <1 mi |
| A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| MB-105 in Patients With CD5 Positive T-cell Lymphoma | Phase 2 | March Biosciences Inc | <1 mi |
| A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | Phase 1 | Solu Therapeutics, Inc | <1 mi |
| A Comparison of Healthcare Provider and Caregiver Perception of Discomfort in Advanced Cancer Patients Who Have a Hypoactive Delirium | — | M.D. Anderson Cancer Center | <1 mi |
| FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. | Phase 1 | Sun Pharma Advanced Research Company Limited | <1 mi |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | Phase 2 | AstraZeneca | <1 mi |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | <1 mi |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours | Phase 1/2 | AstraZeneca | <1 mi |
| A Study of EP0031 in Patients With Advanced RET-altered Malignancies | Phase 1/2 | Ellipses Pharma | <1 mi |
| Collection of Samples USOPTIVAL Study | — | Universal Diagnostics | <1 mi |
| First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma | Phase 1/2 | Adcendo ApS | <1 mi |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer | Phase 2 | The Methodist Hospital Research Institute | <1 mi |
| Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS | Phase 1/2 | ARCE Therapeutics, Inc. | <1 mi |
| Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | Phase 2 | Taiho Oncology, Inc. | <1 mi |
| A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | Phase 1 | Gilead Sciences | <1 mi |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Phase 2/3 | Replimune Inc. | <1 mi |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | Phase 2 | AstraZeneca | <1 mi |
| Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial | — | M.D. Anderson Cancer Center | <1 mi |
| A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL | Phase 2 | Ascentage Pharma Group Inc. | <1 mi |
| HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer | Phase 1/2 | The Methodist Hospital Research Institute | <1 mi |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Phase 1 | Kura Oncology, Inc. | <1 mi |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | Phase 3 | GlaxoSmithKline | <1 mi |
| Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Phase 1/2 | IDEAYA Biosciences | <1 mi |
| A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer | Phase 1/2 | SURGE Therapeutics | <1 mi |
| Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs | Phase 1 | Cellenkos, Inc. | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | Phase 2/3 | BioNTech SE | <1 mi |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer | Phase 3 | Curium US LLC | <1 mi |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma | Phase 1/2 | Oncorena AB | <1 mi |
| Health Benefits of Writing Therapy Among Asian American Cancer Survivors | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors | Phase 2 | Day One Biopharmaceuticals, Inc. | <1 mi |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | Phase 3 | Immunocore Ltd | <1 mi |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Celgene | <1 mi |
| Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology | Phase 2/3 | M.D. Anderson Cancer Center | <1 mi |
| Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors | — | M.D. Anderson Cancer Center | <1 mi |
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | Phase 2 | Protara Therapeutics | <1 mi |
| Comprehensive Assessment of Cancer Theranostic Response | N/A | AIQ Solutions | <1 mi |
| Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology | — | M.D. Anderson Cancer Center | <1 mi |
| Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia | Phase 2 | Theradex | <1 mi |
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Phase 1/2 | Rigel Pharmaceuticals | <1 mi |
| Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma | — | M.D. Anderson Cancer Center | <1 mi |
| Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors | Phase 1 | BeiGene | <1 mi |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Phase 1/2 | Disc Medicine, Inc | <1 mi |
| Active Living After Cancer: Implementation Within Be Well Acres Homes | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Multi Center Study of Sexual Toxicities After Radiotherapy | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | Phase 3 | AstraZeneca | <1 mi |
| Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes | Phase 1 | GluBio Therapeutics Inc. | <1 mi |
| A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | Phase 2 | VA Office of Research and Development | <1 mi |
| Hypofractionated Radiation Therapy for Merkel Cell Carcinoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | Phase 3 | TransThera Sciences (Nanjing), Inc. | <1 mi |
| A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of YL242 in Subjects With Advanced Solid Tumors | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | <1 mi |
| Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC) | — | Universitaire Ziekenhuizen KU Leuven | <1 mi |
| JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | Phase 1/2 | Jacobio Pharmaceuticals Co., Ltd. | <1 mi |
| A Study of Intra-operative Imaging in Women With Ovarian Cancer | Phase 3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer | Phase 2/3 | VA Office of Research and Development | <1 mi |
| Mapping of Human Cognition | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Phase 3 | Verastem, Inc. | <1 mi |
| Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | Phase 2 | Canadian Cancer Trials Group | <1 mi |
| HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | Phase 1 | Baylor College of Medicine | <1 mi |
| Study for AZD4360 in Participants With Advanced Solid Tumours | Phase 1/2 | AstraZeneca | <1 mi |
| Study of Olverembatinib (HQP1351) in Patients With CP-CML | Phase 3 | Ascentage Pharma Group Inc. | <1 mi |
| A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| Vitaccess Real MG Registry | — | Vitaccess Ltd | <1 mi |
| Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States | Phase 2 | Baylor College of Medicine | <1 mi |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 1 | Hoffmann-La Roche | <1 mi |
| Investigations of Reproductive Cancers in Women | — | PinkDx, Inc. | <1 mi |
| PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | Phase 2 | AstraZeneca | <1 mi |
| Web-Based Program in Helping Patients With Head and Neck Cancer Adhere to Swallowing Exercises and Coping Strategies | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | Phase 4 | Janssen Research & Development, LLC | <1 mi |
| A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Day One Biopharmaceuticals, Inc. | <1 mi |
| Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL) | Phase 1 | Baylor College of Medicine | <1 mi |
| Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors | Phase 1/2 | Pyxis Oncology, Inc | <1 mi |
| Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | Early 1 | Nationwide Children's Hospital | <1 mi |
| A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | Early 1 | AIDS Malignancy Consortium | <1 mi |
| Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK) | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | <1 mi |
| Rice Technologies for Cervical Cancer Screening and Diagnosis | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors | Phase 1 | MediLink Therapeutics (Suzhou) Co., Ltd. | <1 mi |
| APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | Early 1 | Ascentage Pharma Group Inc. | <1 mi |
| A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | Phase 1 | Biohaven Therapeutics Ltd. | <1 mi |
| A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | Phase 2/3 | Taiho Oncology, Inc. | <1 mi |
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | Phase 1 | C4 Therapeutics, Inc. | <1 mi |
| INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | Phase 2 | Patrick Wen, MD | <1 mi |
| Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Sentinel Node Biopsy in Endometrial Cancer | Phase 3 | Queensland Centre for Gynaecological Cancer | <1 mi |
| A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Phase 1 | Vividion Therapeutics, Inc. | <1 mi |
| Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study | — | Mohammad H. Abu Arja | <1 mi |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | Phase 1 | SciTech Development, Inc. | <1 mi |
| A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases | Phase 1 | A2A Pharmaceuticals Inc. | <1 mi |
| A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors | Phase 1 | Daiichi Sankyo | <1 mi |
| Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors | Phase 1/2 | Everest Medicines (Beijing) Co., Ltd. | <1 mi |
| Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer | N/A | Alpha Tau Medical LTD. | <1 mi |
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors | Phase 1/2 | OBI Pharma, Inc | <1 mi |
| Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | Phase 1 | Children's Oncology Group | <1 mi |
| International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | Phase 3 | Institute of Cancer Research, United Kingdom | <1 mi |
| Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS | Phase 1 | Shanghai YingLi Pharmaceutical Co. Ltd. | <1 mi |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | Phase 1/2 | CRISPR Therapeutics | <1 mi |
| A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer. | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | Phase 1 | Nuvalent Inc. | <1 mi |
| The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| A Study of BGB-11417 in Participants With Myeloid Malignancies | Phase 1/2 | BeiGene | <1 mi |
| Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial | N/A | Dana-Farber Cancer Institute | <1 mi |
| Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia | Phase 1/2 | AstraZeneca | <1 mi |
| A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | Phase 3 | Merus B.V. | <1 mi |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | Phase 3 | BeOne Medicines | <1 mi |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| ATRA and Carfilzomib in Plasma Cell Myeloma Patients | Phase 1/2 | The Methodist Hospital Research Institute | <1 mi |
| Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | Phase 2 | Stingray Therapeutics | <1 mi |
| A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias | Phase 1 | Crossbow Therapeutics, Inc. | <1 mi |
| A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | <1 mi |
| Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies | Phase 1 | Vincerx Pharma, Inc. | <1 mi |
| Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | Phase 2 | Nationwide Children's Hospital | <1 mi |
| Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors | — | M.D. Anderson Cancer Center | <1 mi |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies | Phase 1/2 | Ipsen | <1 mi |
| Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 1/2 | Imunon | <1 mi |
| Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study. | Phase 4 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia | Phase 1 | Enliven Therapeutics | <1 mi |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | Phase 1 | Ascentage Pharma Group Inc. | <1 mi |
| A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer | Early 1 | M.D. Anderson Cancer Center | <1 mi |
| Measuring Surgical Recovery After Radical Cystectomy | — | M.D. Anderson Cancer Center | <1 mi |
| Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | Phase 1/2 | Phanes Therapeutics | <1 mi |
| A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | Phase 2 | Pierre Fabre Medicament | <1 mi |
| A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis | — | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | <1 mi |
| Examining the Feasibility and Impact of a Clinic-based Food Farmacy and Digital Culinary Medicine Program Among Cancer Survivors Treated in a Safety Net Hospital | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) | Phase 1 | Amgen | <1 mi |
| A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in Patients With Advanced Cancer: a Pilot Clinical Trial | N/A | M.D. Anderson Cancer Center | <1 mi |
| Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer | Phase 2 | University of British Columbia | <1 mi |
| Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | AbbVie | <1 mi |
| GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma | Phase 1 | Baylor College of Medicine | <1 mi |
| Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER | Phase 2 | Baylor College of Medicine | <1 mi |
| Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients | Phase 1 | Theolytics Limited | <1 mi |
| Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas | Phase 1 | Baylor College of Medicine | <1 mi |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | Phase 3 | RayzeBio, Inc. | <1 mi |
| Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | Phase 1/2 | Vivace Therapeutics, Inc | <1 mi |
| Customized 3D Printed Oral Stents During Head and Neck Radiotherapy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | Phase 1/2 | David Baskin MD | <1 mi |
| A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases | Phase 3 | Rakuten Medical, Inc. | <1 mi |
| Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors | Phase 4 | M.D. Anderson Cancer Center | <1 mi |
| Study of AUBE00 in Patients With Solid Tumors | Phase 1 | Chugai Pharmaceutical | <1 mi |
| A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | <1 mi |
| Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | Phase 2 | Swedish Orphan Biovitrum | <1 mi |
| Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma | Phase 1 | New York Medical College | <1 mi |
| A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) | Phase 1 | AstraZeneca | <1 mi |
| High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers | Phase 2 | VA Office of Research and Development | <1 mi |
| A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy. | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Phase 2 | AbbVie | <1 mi |
| Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | — | UroGen Pharma Ltd. | <1 mi |
| Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections | N/A | Medtronic - MITG | <1 mi |
| A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Kyntra Bio | <1 mi |
| Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis | — | M.D. Anderson Cancer Center | <1 mi |
| SNV1521 in Participants with Advanced Solid Tumors | Phase 1 | Synnovation Therapeutics, Inc. | <1 mi |
| Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas | Phase 1 | Bantam Pharmaceuticals | <1 mi |
| realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL | — | Incyte Corporation | <1 mi |
| Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors | Phase 1 | Ningbo Newbay Technology Development Co., Ltd | <1 mi |
| CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) | Phase 1 | CERo Therapeutics Holdings, Inc. | <1 mi |
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis | — | University of Zurich | <1 mi |
| TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas | Phase 1 | Treeline Biosciences, Inc. | <1 mi |
| A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma | Phase 1 | AstraZeneca | <1 mi |
| S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors | Phase 1/2 | Shionogi | <1 mi |
| PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) | Phase 2 | Pulmotect, Inc. | <1 mi |
| Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma | Phase 2 | The University of Texas Health Science Center, Houston | <1 mi |
| Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers | — | M.D. Anderson Cancer Center | <1 mi |
| A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases | Phase 1 | Arcellx, Inc. | <1 mi |
| EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors | Phase 1/2 | Eikon Therapeutics | <1 mi |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | <1 mi |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | Phase 3 | BeiGene | <1 mi |
| Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure | N/A | M.D. Anderson Cancer Center | <1 mi |
| Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Collection and Storage of Tissue and Blood Samples From Patients With Cancer | — | National Cancer Institute LAO | <1 mi |
| A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Prospective Study of Conventional Bone Marrow Biopsy Versus Portomar(TM) Biopsy | N/A | Aperture Medical Technology, LLC | <1 mi |
| Virtual Home-based Exercise Intervention (RISE) to Improve Cancer-Related Cognitive Impairment and Gut Microbiome in Adolescent and Young Adult Brain Tumor Survivors | N/A | Emory University | <1 mi |
| APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | Phase 1 | Aptevo Therapeutics | <1 mi |
| Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells | Phase 1 | Baylor College of Medicine | <1 mi |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Phase 1 | Newave Pharmaceutical Inc | <1 mi |
| A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Phase 1 | Institut de Recherches Internationales Servier | <1 mi |
| A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. | Phase 1 | FoRx Therapeutics AG | <1 mi |
| Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body | N/A | M.D. Anderson Cancer Center | <1 mi |
| Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | Phase 3 | Clarity Pharmaceuticals Ltd | <1 mi |
| Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas | — | M.D. Anderson Cancer Center | <1 mi |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors | N/A | M.D. Anderson Cancer Center | <1 mi |
| Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Vir Biotechnology, Inc. | <1 mi |
| Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | Phase 1/2 | VBI Vaccines Inc. | <1 mi |
| First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | Phase 1 | IDRx Inc. - A GSK Company | <1 mi |
| A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy | — | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | <1 mi |
| Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors | Phase 1 | Qualigen Theraputics, Inc. | <1 mi |
| Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | Phase 1 | EMD Serono Research & Development Institute, Inc. | <1 mi |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors | — | M.D. Anderson Cancer Center | <1 mi |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism | Phase 3 | Rezolute | <1 mi |
| A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM | Phase 1 | Boston Scientific Corporation | <1 mi |
| A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | Phase 3 | Epizyme, Inc. | <1 mi |
| Self-monitoring Focus Groups With Vibrant Lives Pasadena Participants | — | M.D. Anderson Cancer Center | <1 mi |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Phase 1/2 | Nuvalent Inc. | <1 mi |
| Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 | Phase 1 | NextPoint Therapeutics, Inc. | <1 mi |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | <1 mi |
| Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma | Phase 1 | Orbus Therapeutics, Inc. | <1 mi |
| Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors | Phase 2 | Emory University | <1 mi |
| Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain | Phase 1 | Telix Pharmaceuticals (Innovations) Pty Limited | <1 mi |
| Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Phase 1 | SIRPant Immunotherapeutics, Inc. | <1 mi |
| Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML | Phase 1 | Hemogenyx Pharmaceuticals LLC | <1 mi |
| SNV4818 in Participants With Advanced Solid Tumors | Phase 1/2 | Pikavation Therapeutics, Inc. | <1 mi |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | Phase 1/2 | Dren Bio | <1 mi |
| Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies | Phase 3 | The Methodist Hospital Research Institute | <1 mi |
| Blue Light Cystoscopy With Cysview® Registry | — | Photocure | <1 mi |
| Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL | Phase 2 | Etan Orgel | <1 mi |
| Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | Phase 2 | Eli Lilly and Company | <1 mi |
| A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | Early 1 | Nationwide Children's Hospital | <1 mi |
| A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | Phase 2 | Nationwide Children's Hospital | <1 mi |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | Kura Oncology, Inc. | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | Phase 2 | Bio-Path Holdings, Inc. | <1 mi |
| Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant | Phase 1 | Huda Salman | <1 mi |
| A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy | N/A | M.D. Anderson Cancer Center | <1 mi |
| Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Targeted Pediatric High-Grade Glioma Therapy | — | Nationwide Children's Hospital | <1 mi |
| Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers | N/A | M.D. Anderson Cancer Center | <1 mi |
| Pilot Study of Management of Facial Paralysis in the Oncologic Patient: Nerve Transfer Techniques to Improve Facial Function and Quality of Life | N/A | M.D. Anderson Cancer Center | <1 mi |
| Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA) | — | M.D. Anderson Cancer Center | <1 mi |
| Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant | N/A | M.D. Anderson Cancer Center | <1 mi |
| Psychophysical Studies of Cancer Therapy Pain | — | M.D. Anderson Cancer Center | <1 mi |
| LET Optimized IMPT in Treating Pediatric Patients With Ependymoma | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing | — | M.D. Anderson Cancer Center | <1 mi |
| Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) | N/A | National Cancer Institute (NCI) | <1 mi |
| A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients | Phase 2 | Teligene US | <1 mi |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Kura Oncology, Inc. | <1 mi |
| A Study in Patients With Advanced Cancers | Phase 1/2 | BiOneCure Therapeutics Inc. | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Study of EBC-129 in Advanced Solid Tumours | Phase 1 | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | <1 mi |
| Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer | Phase 1 | Nerviano Medical Sciences | <1 mi |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | Phase 1 | Janux Therapeutics | <1 mi |
| Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations | Phase 1 | Tyra Biosciences, Inc | <1 mi |
| Fasting Insulin and HOMA-IR by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis | — | Lilli Health | <1 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Phase 3 | Eli Lilly and Company | <1 mi |
| KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases | Phase 3 | Khondrion BV | <1 mi |
| A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | Phase 2 | Eli Lilly and Company | <1 mi |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Phase 2 | Eli Lilly and Company | <1 mi |
| Rare and Atypical Diabetes Network | — | University of South Florida | <1 mi |
| Adapting and Assessing the Feasibility of a Telehealth Diabetes Prevention Program for Hispanic Adolescents | N/A | Baylor College of Medicine | <1 mi |
| Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers | N/A | Piomic Medical | <1 mi |
| iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes | Phase 1/2 | City of Hope Medical Center | <1 mi |
| Arginine Metabolism in Youth With Type 2 Diabetes | N/A | Baylor College of Medicine | <1 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone | N/A | Capsicure, LLC | <1 mi |
| Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility | N/A | Hamad Medical Corporation | <1 mi |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases | Phase 2 | Walden Biosciences | <1 mi |
| Bionic Pancreas in CFRD | Phase 3 | Jaeb Center for Health Research | <1 mi |
| DISCOVERY of Risk Factors for Type 2 Diabetes in Youth | — | George Washington University | <1 mi |
| A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer | Phase 3 | Energenesis Biomedical Co., Ltd. | <1 mi |
| DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes | Phase 4 | Ohio State University | <1 mi |
| CAMP RWE Trial: Amnion Grafts for Healing Hard-to-Heal Ulcers in RW Populations | N/A | Capsicure, LLC | <1 mi |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | <1 mi |
| RESET System Pivotal Trial (Rev F) | N/A | Morphic Medical Inc. | <1 mi |
| A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | Phase 3 | NewAmsterdam Pharma | <1 mi |
| Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | Phase 2 | Abliva AB | <1 mi |
| Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing | Phase 4 | BioXTek | <1 mi |
| Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) | — | Jaeb Center for Health Research | <1 mi |
| TrialNet Pathway to Prevention of T1D | — | University of South Florida | <1 mi |
| Effect of Increased Physical Activity and Stopping Evening Snacking in Metabolic Health in Youth With Prediabetes | N/A | Baylor College of Medicine | <1 mi |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | Phase 3 | Novo Nordisk A/S | <1 mi |
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | Phase 2 | SAb Biotherapeutics, Inc. | <1 mi |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL | Phase 4 | HealthTech Wound Care | <1 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | <1 mi |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | <1 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | <1 mi |
| Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial | N/A | Baylor College of Medicine | <1 mi |
| EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes | N/A | Baylor College of Medicine | <1 mi |
| Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) | — | M.D. Anderson Cancer Center | <1 mi |
| PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents | N/A | Baylor College of Medicine | <1 mi |
| Immune Function and the Progression to T1D | — | University of Florida | <1 mi |
| Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial | N/A | Sonavex, Inc. | <1 mi |
| CGM for Management of Type 2 Diabetes in Pregnancy | N/A | University of Alabama at Birmingham | <1 mi |
| Functional Connectivity Alterations in Suicidal Patients Among Opioid Users | N/A | Baylor College of Medicine | <1 mi |
| Improving Behavioral Health for Caregivers and Children After Pediatric Injury | N/A | Medical University of South Carolina | <1 mi |
| DBS for Depression | N/A | Baylor College of Medicine | <1 mi |
| Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality | Phase 2 | The University of Texas Health Science Center, Houston | <1 mi |
| Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | <1 mi |
| Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O) | N/A | Baylor College of Medicine | <1 mi |
| Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia | N/A | GrayMatters Health Ltd. | <1 mi |
| Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression | Phase 1 | The University of Texas Health Science Center, Houston | <1 mi |
| MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression | N/A | VA Office of Research and Development | <1 mi |
| Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Phase 3 | Intra-Cellular Therapies, Inc. | <1 mi |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Phase 3 | Cybin IRL Limited | <1 mi |
| Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) | N/A | Abbott Medical Devices | <1 mi |
| Neurobehavioral Therapy For Epilepsy And Major Depressive Disorder | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Deep Brain Stimulation of Treatment-Resistant Bipolar Depression | N/A | Wayne Goodman MD | <1 mi |
| Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Phase 3 | Cybin IRL Limited | <1 mi |
| Transcutaneous Vagus Nerve Stimulation for Attention and Memory | N/A | Baylor College of Medicine | <1 mi |
| Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD) | N/A | Joao L. DeQuevedo | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | Phase 2 | AbbVie | <1 mi |
| Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing | N/A | Baylor College of Medicine | <1 mi |
| Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Phase 2 | ACADIA Pharmaceuticals Inc. | <1 mi |
| Intracranial Investigation of Neural Circuity Underlying Human Mood | N/A | Baylor College of Medicine | <1 mi |
| Study to Assess the Safety and Effectiveness of NMRA-335140-501 | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| ALTO-100 in Bipolar Disorder With Depression (BD-D) | Phase 2 | Alto Neuroscience | <1 mi |
| Telehealth Behavioral Activation for Teens | N/A | Baylor College of Medicine | <1 mi |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Phase 2 | Celgene | <1 mi |
| Phase II Clinical Trial of Interleukin-2 in AD | Phase 2 | The Methodist Hospital Research Institute | <1 mi |
| Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia | — | GAP Innovations, PBC | <1 mi |
| Longitudinal Early-onset Alzheimer's Disease Study Protocol | — | Indiana University | <1 mi |
| Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease | N/A | Baylor College of Medicine | <1 mi |
| Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease | Early 1 | Baylor College of Medicine | <1 mi |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Phase 3 | Annovis Bio Inc. | <1 mi |
| Epidemiology and Biomarker Study in Alzheimer's Disease | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type | Phase 3 | Suven Life Sciences Limited | <1 mi |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| Open-label Extension Study in Participants With Early Alzheimer's Disease | Phase 2 | GlaxoSmithKline | <1 mi |
| Stem Cell Therapy for Early Alzheimer's Disease | Phase 1/2 | Paul E Schulz | <1 mi |
| Smartphone-based Cognitive Emotion Regulation Training for Unpaid Primary Caregivers of Persons With Alzheimer's Disease | N/A | Bryan Denny | <1 mi |
| Systemic and Central Inflammation in AD | Phase 2 | The Methodist Hospital Research Institute | <1 mi |
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Phase 3 | Hoffmann-La Roche | <1 mi |
| Aleniglipron Phase 2 in Type 2 Diabetes Mellitus | Phase 2 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | <1 mi |
| Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study | Early 1 | M.D. Anderson Cancer Center | <1 mi |
| Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass | N/A | Boston Scientific Corporation | <1 mi |
| AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions | N/A | Boston Scientific Corporation | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Phase 3 | Lexicon Pharmaceuticals | <1 mi |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | <1 mi |
| 18F-mFBG Cardiac Uptake With Lewy Body Dementia | Phase 2 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | <1 mi |
| The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial | Phase 4 | VA Office of Research and Development | <1 mi |
| Clinical and Biochemical Effects of a Defined Plant-Based Diet on Heart Disease | N/A | Georgia State University | <1 mi |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | <1 mi |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | <1 mi |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | <1 mi |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children | — | University of Pennsylvania | <1 mi |
| Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study) | N/A | Gradient Denervation Technologies | <1 mi |
| The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) | Phase 2 | Milestone Pharmaceuticals Inc. | <1 mi |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | <1 mi |
| Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy | Phase 2 | Roberto Bolli | <1 mi |
| CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry | — | Universitätsklinikum Hamburg-Eppendorf | <1 mi |
| SPHERE Per-AF Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | <1 mi |
| North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | — | Columbia University | <1 mi |
| An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System | N/A | HighLife SAS | <1 mi |
| Tracking Results of Ablations to Combat AF Registry Generation 2 | — | AtriCure, Inc. | <1 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | <1 mi |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | <1 mi |
| Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure | N/A | Abbott Medical Devices | <1 mi |
| J-Valve Transfemoral Pivotal Study | N/A | JC Medical, Inc., an affiliate of Edwards Lifesciences LLC | <1 mi |
| PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III | N/A | Endotronix, Inc. | <1 mi |
| Inspiring New Science In Guiding Healthcare in Turner Syndrome Registry | — | University of Colorado, Denver | <1 mi |
| DeBakey Cardiovascular Magnetic Resonance Study | — | Dipan Shah | <1 mi |
| The ENCIRCLE Trial | N/A | Edwards Lifesciences | <1 mi |
| UTHealth Turner Syndrome Research Registry | — | The University of Texas Health Science Center, Houston | <1 mi |
| Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure | N/A | Procyrion | <1 mi |
| PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR | N/A | Edwards Lifesciences | <1 mi |
| Prevail Global Study | N/A | Medtronic Vascular | <1 mi |
| An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis | Phase 2 | Zomagen Biosciences Ltd. | <1 mi |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Alnylam Pharmaceuticals | <1 mi |
| Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure | Phase 1 | YAP Therapeutics, Inc. | <1 mi |
| A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy | Phase 2 | Imbria Pharmaceuticals, Inc. | <1 mi |
| Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants | N/A | Nationwide Children's Hospital | <1 mi |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Phase 3 | Intellia Therapeutics | <1 mi |
| The JenaValve ALIGN-AR LVAD Registry | N/A | JenaValve Technology, Inc. | <1 mi |
| ATrial Tachycardia PAcing Therapy in Congenital Heart | — | Ian Law | <1 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis | Phase 2/3 | CSL Behring | <1 mi |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | <1 mi |
| A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | Phase 3 | Bayer | <1 mi |
| Medtronic Cardiac Surgery PMCF Registry | — | Medtronic Cardiac Surgery | <1 mi |
| PARTNER 3 Trial - Aortic Valve-in-Valve | N/A | Edwards Lifesciences | <1 mi |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | N/A | W.L.Gore & Associates | <1 mi |
| Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy | — | Tenaya Therapeutics | <1 mi |
| The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study | N/A | Brigham and Women's Hospital | <1 mi |
| Symptom Burden and Health Related Quality of Life of Cancer Patients With Concurrent Heart Failure | — | M.D. Anderson Cancer Center | <1 mi |
| Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement | N/A | University of British Columbia | <1 mi |
| A Phase 2 Study of CRD-4730 in CPVT | Phase 2 | Cardurion Pharmaceuticals, Inc. | <1 mi |
| Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM | Phase 1/2 | Tenaya Therapeutics | <1 mi |
| The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients | Phase 4 | University of Rochester | <1 mi |
| TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I) | N/A | P+F Products + Features USA Inc. | <1 mi |
| CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) | Phase 3 | Cardiol Therapeutics Inc. | <1 mi |
| REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | — | Medtronic Cardiovascular | <1 mi |
| Cephea Early Feasibility Study | N/A | Abbott Medical Devices | <1 mi |
| Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial) | Phase 2 | The University of Texas Health Science Center, Houston | <1 mi |
| Cord Clamping Among Neonates With Congenital Heart Disease | N/A | Carl Backes, MD | <1 mi |
| LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 | Phase 3 | Tenax Therapeutics, Inc. | <1 mi |
| Identification of Genomic Predictors of Adverse Events After Cardiac Surgery | — | Brigham and Women's Hospital | <1 mi |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR | N/A | Cardiac Dimensions, Inc. | <1 mi |
| Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block | — | The Hospital for Sick Children | <1 mi |
| Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress | Phase 4 | Population Health Research Institute | <1 mi |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | <1 mi |
| HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry | — | University of Kansas Medical Center | <1 mi |
| A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old. | Phase 4 | Pfizer | <1 mi |
| Product Surveillance Registry | — | Medtronic | <1 mi |
| Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED) | — | VDI Technologies | <1 mi |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | <1 mi |
| Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Bristol-Myers Squibb | <1 mi |
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| BiVACOR® Total Artificial Heart Early Feasibility Study | N/A | BiVACOR Inc. | <1 mi |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Phase 3 | X4 Pharmaceuticals | <1 mi |
| Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study | N/A | Ancora Heart, Inc. | <1 mi |
| ViewFlex X ICE First-in-Human Study | — | Abbott Medical Devices | <1 mi |
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase 3 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | <1 mi |
| Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery | Phase 1 | Pacira Pharmaceuticals, Inc | <1 mi |
| Danon Disease Natural History Study | — | Rocket Pharmaceuticals Inc. | <1 mi |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | Phase 3 | Massachusetts General Hospital | <1 mi |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | <1 mi |
| FORWARD CAD IDE Study | N/A | Shockwave Medical, Inc. | <1 mi |
| ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves | N/A | Edwards Lifesciences | <1 mi |
| MYTHS - MYocarditis THerapy With Steroids | Phase 3 | Niguarda Hospital | <1 mi |
| A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | <1 mi |
| Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Phase 2/3 Study of KPL-387 in Recurrent Pericarditis | Phase 2/3 | Kiniksa Pharmaceuticals International, plc | <1 mi |
| AMEND TS Early Feasibility Study | N/A | Valcare Medical Ltd. | <1 mi |
| Randomized Trial of SGLT2i in Heart Transplant Recipients | Phase 4 | VA Office of Research and Development | <1 mi |
| TTVR Early Feasibility Study | N/A | Medtronic Cardiovascular | <1 mi |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | <1 mi |
| Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study | — | Centre hospitalier de l'Université de Montréal (CHUM) | <1 mi |
| Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs | — | Inova Health Care Services | <1 mi |
| Outcomes and Health Care Resource Utilization in Pediatric Congenital Heart Disease Patients Undergoing Non-Cardiac Procedures | — | Boston Children's Hospital | <1 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | <1 mi |
| AltaValve Pivotal Trial | N/A | 4C Medical Technologies, Inc. | <1 mi |
| Abbott Cephea Mitral Valve Disease Registry | — | Abbott Medical Devices | <1 mi |
| A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Phase 2 | BioMarin Pharmaceutical | <1 mi |
| The CONFORM Pivotal Trial | N/A | Conformal Medical, Inc | <1 mi |
| Assessment of CCM in HF With Higher Ejection Fraction | N/A | Impulse Dynamics | <1 mi |
| Study of JK07 in Patients With Chronic Heart Failure | Phase 2 | Salubris Biotherapeutics Inc | <1 mi |
| ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | N/A | JenaValve Technology, Inc. | <1 mi |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | Phase 2 | Novo Nordisk A/S | <1 mi |
| Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ) | Phase 3 | NYU Langone Health | <1 mi |
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Phase 2 | Cytokinetics | <1 mi |
| Pivotal Study for the Cardiac Performance System (CPS) | — | Sensydia Corporation | <1 mi |
| Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients | N/A | Baylor College of Medicine | <1 mi |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | N/A | Shockwave Medical, Inc. | <1 mi |
| Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device | Phase 4 | Columbia University | <1 mi |
| A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF) | N/A | Biosense Webster, Inc. | <1 mi |
| Marfan Syndrome Moderate Exercise Trial II | N/A | Baylor College of Medicine | <1 mi |
| Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) | N/A | University of Michigan | <1 mi |
| Transition to KPL-387 Monotherapy Dosing & Administration Study | Phase 2 | Kiniksa Pharmaceuticals International, plc | <1 mi |
| Venous Ethanol for Ventricular Tachycardia | Phase 2 | The Methodist Hospital Research Institute | <1 mi |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | <1 mi |
| A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma | — | Children's Oncology Group | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | Phase 2 | Pfizer | <1 mi |
| Individualizing Treatment for Asthma in Primary Care (Full Study) | Phase 4 | DARTNet Institute | <1 mi |
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Phase 3 | Teva Branded Pharmaceutical Products R&D LLC | <1 mi |
| Metformin IN Asthma for Overweight and Obese Individuals (MINA) | Phase 2 | Johns Hopkins University | <1 mi |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment | Phase 3 | AstraZeneca | <1 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma | Phase 3 | AstraZeneca | <1 mi |
| A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) | Phase 2 | Upstream Bio Inc. | <1 mi |
| Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | Phase 4 | Sanofi | <1 mi |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) | Phase 3 | Generate Biomedicines | <1 mi |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | — | Duke University | <1 mi |
| Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) | Phase 3 | Sanofi | <1 mi |
| A Study to Evaluate Solriktug in Adult Participants With Asthma | Phase 2 | Uniquity One (UNI) | <1 mi |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | Phase 4 | Regeneron Pharmaceuticals | <1 mi |
| Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease | Phase 3 | Vor Biopharma | <1 mi |
| A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | Phase 2 | AbbVie | <1 mi |
| A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy | — | M.D. Anderson Cancer Center | <1 mi |
| Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry | — | Duke University | <1 mi |
| R-2487 in Patients With Rheumatoid Arthritis | Phase 1 | Rise Therapeutics LLC | <1 mi |
| Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty | Phase 4 | The Methodist Hospital Research Institute | <1 mi |
| A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | Phase 2 | Hoffmann-La Roche | <1 mi |
| Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System | N/A | DT MedTech, LLC | <1 mi |
| Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty) | — | Zimmer Biomet | <1 mi |
| A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Phase 4 | Eli Lilly and Company | <1 mi |
| A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic | — | Sonoma Biotherapeutics, Inc. | <1 mi |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout | Phase 3 | Crystalys Therapeutics | <1 mi |
| An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis | Phase 2 | Eli Lilly and Company | <1 mi |
| A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | Phase 3 | Paradigm Biopharmaceuticals Ltd. | <1 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | Phase 3 | Takeda | <1 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | Phase 3 | Eli Lilly and Company | <1 mi |
| RA-PRO PRAGMATIC TRIAL | Phase 3 | University of Alabama at Birmingham | <1 mi |
| Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis | Phase 2 | AbbVie | <1 mi |
| Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis | Phase 3 | Medipost, Inc. | <1 mi |
| Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD | Phase 2 | Johns Hopkins University | <1 mi |
| A Study to Evaluate Solrikitug in Participants With COPD (ZION) | Phase 2 | Uniquity One (UNI) | <1 mi |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Hoffmann-La Roche | <1 mi |
| myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home | N/A | Temple University | <1 mi |
| Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS | N/A | Philip Morris Products S.A. | <1 mi |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Phase 3 | AstraZeneca | <1 mi |
| Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease | N/A | University of Alabama at Birmingham | <1 mi |
| A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | <1 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) | Phase 3 | AstraZeneca | <1 mi |
| Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3 | N/A | Apreo Health, Inc. | <1 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) | Phase 3 | AstraZeneca | <1 mi |
| Expansion and Evaluation of AI-generated Clinical Assessment (AI-COA®) of Depression and Anxiety Severity | N/A | Deliberate Solutions Inc. | <1 mi |
| Pilot Study of Virtual Reality Therapy for Students With Anxiety | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| A Neurosensory Account of Anxiety and Stress (Study 2) | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer | Phase 2/3 | M.D. Anderson Cancer Center | <1 mi |
| Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety | N/A | Baylor College of Medicine | <1 mi |
| Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors | N/A | M.D. Anderson Cancer Center | <1 mi |
| Comparative Effectiveness of Internet-based Versus Parent-Coached Cognitive-Behavioral Therapy For Children and Adolescents With Anxiety and OCD | N/A | Baylor College of Medicine | <1 mi |
| Mobile App for Latinx Hazardous Drinkers With Clinical Anxiety | N/A | Michael J. Zvolensky, Ph.D. | <1 mi |
| A Mobile Intervention for Black Individuals Who Engage in Hazardous Drinking | N/A | University of Houston | <1 mi |
| Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Personalized Feedback Intervention for Latinx Drinkers With Anxiety | N/A | University of Houston | <1 mi |
| Neonatal Neurodevelopmental Outcomes | — | Baylor College of Medicine | <1 mi |
| ERP to Improve Functioning in Veterans With OCD | N/A | VA Office of Research and Development | <1 mi |
| Physiological and Psychological Effects of Music Therapy in the Pregnant Woman and Fetus | N/A | Christina Chianis Reed | <1 mi |
| Integrated CBT to Improve Functioning in Veterans With Anxiety and Substance Use | N/A | VA Office of Research and Development | <1 mi |
| Application of Virtual Reality Technology to Treatment of Social Anxiety | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety | N/A | Baylor College of Medicine | <1 mi |
| Neurophysiological Investigation of the Approach-avoidance Axis in OCD: Applications to Neuromodulation | — | Baylor College of Medicine | <1 mi |
| Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | Phase 3 | Vanda Pharmaceuticals | <1 mi |
| CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD | N/A | Baylor College of Medicine | <1 mi |
| A Neurosensory Account of Anxiety and Stress (Study 1) | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Stepped Care Treatment for Anxiety Resilience | N/A | Andrew Wiese | <1 mi |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) | Phase 3 | VistaGen Therapeutics, Inc. | <1 mi |
| A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications | — | Bayer | <1 mi |
| A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) | Phase 2 | AskBio Inc | <1 mi |
| Black and African Americans Connections to Parkinson's Disease (BLAAC PD) | — | Michael J. Fox Foundation for Parkinson's Research | <1 mi |
| A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | Phase 3 | BlueRock Therapeutics | <1 mi |
| To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | Phase 3 | Cerevance | <1 mi |
| PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort | — | Michael J. Fox Foundation for Parkinson's Research | <1 mi |
| Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | — | Boston Scientific Corporation | <1 mi |
| Parkinson's Foundation PD GENEration Genetic Registry | — | Parkinson's Foundation | <1 mi |
| A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | Phase 2 | Neuron23 Inc. | <1 mi |
| A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease | Phase 4 | Impax Laboratories, LLC | <1 mi |
| Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis | Phase 4 | VA Office of Research and Development | <1 mi |
| RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | Phase 1/2 | Cabaletta Bio | <1 mi |
| A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | Phase 2 | Amgen | <1 mi |
| A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | Phase 2 | Immunovant Sciences GmbH | <1 mi |
| A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | Phase 1/2 | Nkarta, Inc. | <1 mi |
| Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study | Phase 2 | Children's Hospital Medical Center, Cincinnati | <1 mi |
| An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants | Phase 3 | AstraZeneca | <1 mi |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | Phase 2 | Zenas BioPharma (USA), LLC | <1 mi |
| Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | Phase 2 | Darcy Krueger | <1 mi |
| Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Care in Multiple Sclerosis (MS) | — | NYU Langone Health | <1 mi |
| TSC Biosample Repository and Natural History Database | — | National Tuberous Sclerosis Association | <1 mi |
| Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis | Phase 4 | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) | Phase 3 | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS | N/A | The Methodist Hospital Research Institute | <1 mi |
| A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis | Phase 2 | Eli Lilly and Company | <1 mi |
| Study of COYA 302 for the Treatment of ALS | Phase 2 | Coya Therapeutics | <1 mi |
| Multiple Sclerosis Implementation Network (Registry) | — | The University of Texas Health Science Center, Houston | <1 mi |
| AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis | Phase 1 | Amylyx Pharmaceuticals Inc. | <1 mi |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | Phase 3 | Sanofi | <1 mi |
| A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | Phase 1 | Alterome Therapeutics, Inc. | <1 mi |
| Magseed Enabled Long-Term Localization of Axillary Lymph Nodes | N/A | Endomagnetics Ltd. | <1 mi |
| Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | Phase 2 | BicycleTx Limited | <1 mi |
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Phase 1/2 | 858 Therapeutics, Inc. | <1 mi |
| BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | SillaJen, Inc. | <1 mi |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | <1 mi |
| A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| Converting HR+ Breast Cancer Into an Individualized Vaccine | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies | Phase 1/2 | ALX Oncology Inc. | <1 mi |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | Phase 1/2 | Aminex Therapeutics, Inc. | <1 mi |
| Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer | Phase 1/2 | Phoenix Molecular Designs | <1 mi |
| CtDNA Based MRD Testing for NAC Monitoring in TNBC | — | Personalis Inc. | <1 mi |
| Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection | Phase 2 | The Methodist Hospital Research Institute | <1 mi |
| A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC) | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| Everyday Exposures: How Chemicals and Weight Impact Breast Cancer Risk | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Phase 1 | Relay Therapeutics, Inc. | <1 mi |
| An Ophthalmic Safety Study in Patients With Breast Cancer | — | AstraZeneca | <1 mi |
| First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Phase 1/2 | Eli Lilly and Company | <1 mi |
| Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | Phase 1/2 | Stemline Therapeutics, Inc. | <1 mi |
| A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | Phase 1 | Olema Pharmaceuticals, Inc. | <1 mi |
| Study of 68Ga-R10602 | Phase 1 | Radionetics Oncology | <1 mi |
| Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study | — | M.D. Anderson Cancer Center | <1 mi |
| Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | Phase 2 | Vanderbilt-Ingram Cancer Center | <1 mi |
| Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | Phase 1 | Qurgen Inc. | <1 mi |
| Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions | N/A | ARTIDIS AG | <1 mi |
| TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd | Phase 2 | Ana C Garrido-Castro, MD | <1 mi |
| Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics. | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Phase 1/2 | AstraZeneca | <1 mi |
| A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer | Phase 1 | Edgewood Oncology Inc. | <1 mi |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer | Phase 1 | Radionetics Oncology | <1 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | <1 mi |
| Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | Phase 2 | Massachusetts General Hospital | <1 mi |
| Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy | N/A | M.D. Anderson Cancer Center | <1 mi |
| An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Phase 3 | AstraZeneca | <1 mi |
| Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response | — | Sunnybrook Health Sciences Centre | <1 mi |
| A Study of XMT-1660 in Participants With Solid Tumors | Phase 1 | Mersana Therapeutics | <1 mi |
| Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue | — | M.D. Anderson Cancer Center | <1 mi |
| Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | Phase 2 | Baylor Breast Care Center | <1 mi |
| Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Phase 1 | Avacta Life Sciences Ltd | <1 mi |
| Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer | Phase 1/2 | Incyclix Bio | <1 mi |
| TRUDI: TDXD+Durva in HER2+/Low IBC | Phase 2 | Filipa Lynce, MD | <1 mi |
| Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | Phase 2 | The Methodist Hospital Research Institute | <1 mi |
| Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | <1 mi |
| Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma | N/A | M.D. Anderson Cancer Center | <1 mi |
| Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ | Phase 3 | Uppsala University | <1 mi |
| Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | Phase 1 | Accent Therapeutics | <1 mi |
| PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer | Phase 1 | ProteinQure Inc. | <1 mi |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Phase 3 | Sermonix Pharmaceuticals Inc. | <1 mi |
| The PREDICT Registry: | — | PreludeDx | <1 mi |
| A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | Phase 1/2 | Boehringer Ingelheim | <1 mi |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | <1 mi |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | Phase 3 | AstraZeneca | <1 mi |
| Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI) | N/A | M.D. Anderson Cancer Center | <1 mi |
| Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen | — | M.D. Anderson Cancer Center | <1 mi |
| A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 2 | Bayer | <1 mi |
| BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer | Phase 1 | BeOne Medicines | <1 mi |
| Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | Phase 1 | OncoNano Medicine, Inc. | <1 mi |
| Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | Phase 1/2 | Ensem Therapeutics | <1 mi |
| The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts | N/A | M.D. Anderson Cancer Center | <1 mi |
| PRE-I-SPY Phase I/Ib Oncology Platform Program | Phase 1 | QuantumLeap Healthcare Collaborative | <1 mi |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | Phase 3 | AstraZeneca | <1 mi |
| A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. | Phase 1/2 | Eikon Therapeutics | <1 mi |
| Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery | Phase 2/3 | M.D. Anderson Cancer Center | <1 mi |
| Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Phase 3 | Relay Therapeutics, Inc. | <1 mi |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | <1 mi |
| Multi-center MRD Registry for Inflammatory Breast Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Phase 3 | Celcuity Inc | <1 mi |
| Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies | Phase 1 | Duke Street Bio Ltd | <1 mi |
| EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE) | N/A | Breast Cancer Trials, Australia and New Zealand | <1 mi |
| Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | Phase 2 | The Methodist Hospital Research Institute | <1 mi |
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | <1 mi |
| Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | Phase 1/2 | Stemline Therapeutics, Inc. | <1 mi |
| Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer | Phase 1 | Boundless Bio, Inc. | <1 mi |
| Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics | — | M.D. Anderson Cancer Center | <1 mi |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | Early 1 | Presage Biosciences | <1 mi |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| Breast Mesh Used in Two-staged Breast Reconstruction | N/A | Tianjin Medical University Cancer Institute and Hospital | <1 mi |
| A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | Phase 1/2 | AstraZeneca | <1 mi |
| SLV-154 Treatment of Metastatic Solid Tumors | Phase 1 | Solve Therapeutics | <1 mi |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Phase 1 | Exelixis | <1 mi |
| Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer | Phase 1 | OncoTherapy Science, Inc. | <1 mi |
| LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge) | N/A | Fibralign Corporation | <1 mi |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | Phase 1/2 | AtlasMedx, Incorporated | <1 mi |
| Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer | Phase 1 | Biotheryx, Inc. | <1 mi |
| Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts | N/A | American College of Radiology | <1 mi |
| Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Phase 1/2 | Strand Therapeutics Inc. | <1 mi |
| Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Phase 3 | BioNTech SE | <1 mi |
| Circulating Tumor DNA | Phase 2 | Yale University | <1 mi |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | Phase 2 | Laura Huppert, MD, BA | <1 mi |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | <1 mi |
| ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| Improving Comprehensive Care of Cancer Patients | N/A | Baylor College of Medicine | <1 mi |
| ETHAN - ET for Male BC | Phase 2 | Jose Pablo Leone | <1 mi |
| [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | Phase 1 | Novartis Pharmaceuticals | <1 mi |
| Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) | — | University of California, San Francisco | <1 mi |
| BostonGene and Exigent Genomic INsight Study | — | BostonGene | <1 mi |
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | <1 mi |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | <1 mi |
| A Registry for People With Lung Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 3 | Shanghai Junshi Bioscience Co., Ltd. | <1 mi |
| CPRIT: Patient Adherence to Lung Cancer Screening | — | M.D. Anderson Cancer Center | <1 mi |
| Comprehensive Outcomes for After Cancer Health | N/A | Pack Health | <1 mi |
| A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer | Phase 2 | AbbVie | <1 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | <1 mi |
| Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | Phase 1/2 | IDEAYA Biosciences | <1 mi |
| FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | Phase 1 | Fate Therapeutics | <1 mi |
| SW-682 in Advanced Solid Tumors | Phase 1 | SpringWorks Therapeutics, Inc. | <1 mi |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy | Phase 1 | Abdera Therapeutics Inc. | <1 mi |
| Repositioning Immunotherapy in VetArans With Lung Cancer | Phase 2 | VA Office of Research and Development | <1 mi |
| A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors | Phase 1 | Epkin | <1 mi |
| SMP-3124LP in Adults With Advanced Solid Tumors | Phase 1/2 | Sumitomo Pharma America, Inc. | <1 mi |
| Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes | — | M.D. Anderson Cancer Center | <1 mi |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | <1 mi |
| A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS | Phase 3 | AstraZeneca | <1 mi |
| A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Phase 1 | Bicara Therapeutics | <1 mi |
| Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers | — | Lung Cancer Mutation Consortium | <1 mi |
| Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations | Phase 1/2 | Pierre Fabre Medicament | <1 mi |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | Phase 1/2 | Marengo Therapeutics, Inc. | <1 mi |
| Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer | Phase 1 | The Methodist Hospital Research Institute | <1 mi |
| MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Phase 1/2 | PMV Pharmaceuticals, Inc | <1 mi |
| A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | Phase 1 | Nuvectis Pharma, Inc. | <1 mi |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | Phase 1 | Tizona Therapeutics, Inc | <1 mi |
| A Study of IBI363 in Subjects with Advanced Solid Malignancies | Phase 2 | Innovent Biologics (Suzhou) Co. Ltd. | <1 mi |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer | Phase 1/2 | VA Office of Research and Development | <1 mi |
| Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC | Phase 1/2 | VA Office of Research and Development | <1 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | AstraZeneca | <1 mi |
| Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) | Phase 1 | Amgen | <1 mi |
| A Study of DM001 in Patients With Advanced Solid Tumors | Phase 1 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | <1 mi |
| Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment | Phase 2 | BioNTech SE | <1 mi |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | N/A | VA Office of Research and Development | <1 mi |
| Safety and Durability of Sirolimus for Treatment of LAM | — | University of Cincinnati | <1 mi |
| A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | Phase 1/2 | Alentis Therapeutics AG | <1 mi |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Phase 3 | Amgen | <1 mi |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| A Prospective Single Center, Single Arm, Single-institution Registry That Aims to Assess the Safety and Quality of Life Benefits of Computer-assisted Vacuum Thrombectomy (CAVT) in the Treatment of Cancer Patients With Intermediate Risk Pulmonary Embolism (PE) | N/A | M.D. Anderson Cancer Center | <1 mi |
| Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | Phase 1 | ALX Oncology Inc. | <1 mi |
| Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. | Phase 2 | Taiho Oncology, Inc. | <1 mi |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Phase 1 | Incyte Corporation | <1 mi |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | Phase 1 | Aktis Oncology, Inc. | <1 mi |
| Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | Phase 1 | Whitehawk Therapeutics, Inc. | <1 mi |
| Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers | N/A | M.D. Anderson Cancer Center | <1 mi |
| IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | Phase 2 | Innate Pharma | <1 mi |
| Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors | — | M.D. Anderson Cancer Center | <1 mi |
| Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | Phase 1 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | <1 mi |
| Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | Phase 1/2 | EMD Serono Research & Development Institute, Inc. | <1 mi |
| A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | Phase 1 | BeiGene | <1 mi |
| A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors | Phase 1 | Shanghai Henlius Biotech | <1 mi |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Phase 1 | BeiGene | <1 mi |
| Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC | Phase 1 | AstraZeneca | <1 mi |
| Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | Phase 1/2 | AbbVie | <1 mi |
| A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation | Phase 1/2 | Tyligand Pharmaceuticals (Suzhou) Limited | <1 mi |
| IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed | Phase 3 | Fortvita Biologics (USA)Inc. | <1 mi |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer | — | N-Power Medicine | <1 mi |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Hoffmann-La Roche | <1 mi |
| Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC | Phase 1 | RayzeBio, Inc. | <1 mi |
| Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma | Phase 2 | Hackensack Meridian Health | <1 mi |
| Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 2 | Teligene US | <1 mi |
| Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | Phase 1 | Circle Pharma | <1 mi |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | Phase 1/2 | AstraZeneca | <1 mi |
| A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | Phase 1 | Pfizer | <1 mi |
| A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Phase 1 | BeiGene | <1 mi |
| Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners | N/A | M.D. Anderson Cancer Center | <1 mi |
| Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers | N/A | City of Hope Medical Center | <1 mi |
| A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors | Phase 1/2 | Frontier Medicines Corporation | <1 mi |
| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Phase 2 | Daiichi Sankyo | <1 mi |
| Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Phase 1/2 | Linnaeus Therapeutics, Inc. | <1 mi |
| A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Phase 1 | AstraZeneca | <1 mi |
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Phase 1/2 | Aulos Bioscience, Inc. | <1 mi |
| Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry | — | M.D. Anderson Cancer Center | <1 mi |
| A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study | — | Invenio Imaging Inc. | <1 mi |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | — | A2 Biotherapeutics Inc. | <1 mi |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Phase 3 | OncoC4, Inc. | <1 mi |
| A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations | Phase 1/2 | BlossomHill Therapeutics | <1 mi |
| A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs | Phase 1/2 | Pierre Fabre Medicament | <1 mi |
| The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study) | — | Fred Hutchinson Cancer Center | <1 mi |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| A Beta-only IL-2 ImmunoTherapY Study | Phase 1/2 | Medicenna Therapeutics, Inc. | <1 mi |
| Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | Phase 1 | Novartis Pharmaceuticals | <1 mi |
| Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers | N/A | M.D. Anderson Cancer Center | <1 mi |
| Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers | Phase 1/2 | Synthekine | <1 mi |
| Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery | N/A | M.D. Anderson Cancer Center | <1 mi |
| KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors | Phase 1 | Phrontline Biopharma | <1 mi |
| The Rise in Robotic Atypical Segmentectomies | — | M.D. Anderson Cancer Center | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | Phase 1 | Pfizer | <1 mi |
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | Phase 1 | AstraZeneca | <1 mi |
| Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury | Phase 2 | Hope Biosciences LLC | <1 mi |
| TELESCOPE- TELEhealth Shared Decision-making COaching | N/A | Rutgers, The State University of New Jersey | <1 mi |
| Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities | Phase 1/2 | Taiho Pharmaceutical Co., Ltd. | <1 mi |
| A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | Phase 1 | Novelty Nobility, Inc. | <1 mi |
| Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | Phase 1 | EpiBiologics | <1 mi |
| A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | Phase 1/2 | GV20 Therapeutics | <1 mi |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Phase 1/2 | VM Oncology, LLC | <1 mi |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Phase 1 | Janux Therapeutics | <1 mi |
| Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | <1 mi |
| Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations | Phase 3 | ArriVent BioPharma, Inc. | <1 mi |
| A Phase 1 Study of LNCB74 in Advanced Solid Tumors | Phase 1 | NextCure, Inc. | <1 mi |
| A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | Phase 1 | Incendia Therapeutics | <1 mi |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Phase 1/2 | Verastem, Inc. | <1 mi |
| A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Shanghai Henlius Biotech | <1 mi |
| SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Phase 1 | Verismo Therapeutics | <1 mi |
| Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors | Phase 1 | Calico Life Sciences LLC | <1 mi |
| A Study of PHN-012 in Patients With Advanced Solid Tumors | Phase 1 | Pheon Therapeutics | <1 mi |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | <1 mi |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Phase 1 | Kura Oncology, Inc. | <1 mi |
| A Study of NX-1607 in Adults With Advanced Malignancies | Phase 1 | Nurix Therapeutics, Inc. | <1 mi |
| Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic | — | M.D. Anderson Cancer Center | <1 mi |
| Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | Phase 3 | AstraZeneca | <1 mi |
| PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification | — | M.D. Anderson Cancer Center | <1 mi |
| Study of XB010 in Subjects With Solid Tumors | Phase 1 | Exelixis | <1 mi |
| A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | Phase 1 | Baylor College of Medicine | <1 mi |
| A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | Phase 1/2 | AstraZeneca | <1 mi |
| Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Phase 2 | Mirati Therapeutics Inc. | <1 mi |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer | Phase 3 | Gilead Sciences | <1 mi |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer | Phase 2 | AstraZeneca | <1 mi |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Phase 1 | Bristol-Myers Squibb | <1 mi |
| Adaptation and Pilot Testing of a Lung Cancer Screening Decision Aid for Patients From a Safety-Net Healthcare System | N/A | M.D. Anderson Cancer Center | <1 mi |
| Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer | Phase 1/2 | BioNTech SE | <1 mi |
| A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | Phase 1/2 | Cogent Biosciences, Inc. | <1 mi |
| TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors | Phase 1/2 | Portage Biotech | <1 mi |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer | — | Washington University School of Medicine | <1 mi |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Genentech, Inc. | <1 mi |
| A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | AstraZeneca | <1 mi |
| A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | Phase 1/2 | LigaChem Biosciences, Inc. | <1 mi |
| A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | Phase 2/3 | BioNTech SE | <1 mi |
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 3 | Bayer | <1 mi |
| A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | Phase 3 | AstraZeneca | <1 mi |
| Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer | Phase 1 | Nuvectis Pharma, Inc. | <1 mi |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies | Phase 1 | TopAlliance Biosciences | <1 mi |
| Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) | Phase 1 | Amgen | <1 mi |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | Phase 1/2 | Genprex, Inc. | <1 mi |
| Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab | Phase 1 | AbbVie | <1 mi |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | Phase 1/2 | Arvinas Inc. | <1 mi |
| Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening | — | Freenome Holdings Inc. | <1 mi |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Phase 1 | IDEAYA Biosciences | <1 mi |
| Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | Phase 3 | Nuvation Bio Inc. | <1 mi |
| Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce | — | M.D. Anderson Cancer Center | <1 mi |
| Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Revolution Medicines, Inc. | <1 mi |
| A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | Phase 2/3 | AbbVie | <1 mi |
| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | <1 mi |
| Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2/3 | AbbVie | <1 mi |
| A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Phase 1/2 | Tanabe Pharma America, Inc. | <1 mi |
| A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation | N/A | M.D. Anderson Cancer Center | <1 mi |
| Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | <1 mi |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | Mersana Therapeutics | <1 mi |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors | Phase 1/2 | Obsidian Therapeutics, Inc. | <1 mi |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | Phase 1 | BioNTech SE | <1 mi |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment | — | M.D. Anderson Cancer Center | <1 mi |
| Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study | N/A | M.D. Anderson Cancer Center | <1 mi |
| First in Human Study of AZD9592 in Solid Tumors | Phase 1 | AstraZeneca | <1 mi |
| Educating Smokers About Lung Cancer Screening Using Tobacco Quitlines | N/A | M.D. Anderson Cancer Center | <1 mi |
| ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | Persephone Biosciences | <1 mi |
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | <1 mi |
| A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | Phase 1 | Alterome Therapeutics, Inc. | <1 mi |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | Phase 1/2 | Phanes Therapeutics | <1 mi |
| Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors | Phase 1/2 | AstraZeneca | <1 mi |
| Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | <1 mi |
| KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) | — | Merck Sharp & Dohme LLC | <1 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Phase 3 | Summit Therapeutics | <1 mi |
| AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | Phase 1 | Amgen | <1 mi |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| A Study of LY4175408 in Participants With Advanced Cancer | Phase 1 | Eli Lilly and Company | <1 mi |
| Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders | Phase 2 | Carl Allen | <1 mi |
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Phase 1/2 | Volastra Therapeutics, Inc. | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC | Phase 2 | Teligene US | <1 mi |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Phase 3 | Revolution Medicines, Inc. | <1 mi |
| A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | Phase 1/2 | Terremoto Biosciences Inc. | <1 mi |
| A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Phase 1/2 | BioNTech SE | <1 mi |
| A Study of VET3-TGI in Patients With Solid Tumors | Phase 1 | KaliVir Immunotherapeutics | <1 mi |
| A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Phase 2 | Jazz Pharmaceuticals | <1 mi |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | Phase 3 | Bristol-Myers Squibb | <1 mi |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors | Phase 1 | Pfizer | <1 mi |
| A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| The Impact of COVID-19 on Pulmonary Procedures | — | M.D. Anderson Cancer Center | <1 mi |
| Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study | N/A | AIDS Malignancy Consortium | <1 mi |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | — | Ipsen | <1 mi |
| NAFLD Clinical Care Pathway | N/A | VA Office of Research and Development | <1 mi |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Phase 2 | Mirum Pharmaceuticals, Inc. | <1 mi |
| TReatment for ImmUne Mediated PathopHysiology | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | <1 mi |
| A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 1 | Regeneron Pharmaceuticals | <1 mi |
| High Dose Albumin in Refractory Ascites | Phase 2 | Baylor College of Medicine | <1 mi |
| Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | — | European Foundation for Study of Chronic Liver Failure | <1 mi |
| Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome | Phase 3 | Albireo, an Ipsen Company | <1 mi |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Phase 3 | Ipsen | <1 mi |
| FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study | Phase 2 | Intercept Pharmaceuticals | <1 mi |
| A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | Phase 2 | Boehringer Ingelheim | <1 mi |
| Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Phase 2 | Gilead Sciences | <1 mi |
| Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis | Phase 1/2 | Prasun Kumar Jalal | <1 mi |
| A Prospective Database of Infants With Cholestasis | — | Arbor Research Collaborative for Health | <1 mi |
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Phase 3 | Mirum Pharmaceuticals, Inc. | <1 mi |
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Phase 2 | Altimmune, Inc. | <1 mi |
| Primary Sclerosing Cholangitis in Children | — | Arbor Research Collaborative for Health | <1 mi |
| Liver Disease in Urea Cycle Disorders | — | Baylor College of Medicine | <1 mi |
| A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) | — | Target PharmaSolutions, Inc. | <1 mi |
| Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | Phase 3 | Zydus Therapeutics Inc. | <1 mi |
| Veteran-Centered Care for Advanced Liver Disease (Vet-CALD) | N/A | VA Office of Research and Development | <1 mi |
| Natural History of Wilson Disease | — | Yale University | <1 mi |
| Hepatic Histopathology in Urea Cycle Disorders | — | Baylor College of Medicine | <1 mi |
| Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes | Phase 2 | LyGenesis, Inc. | <1 mi |
| The Myelin Disorders Biorepository Project | — | Children's Hospital of Philadelphia | <1 mi |
| Genetic Collection Protocol | — | Arbor Research Collaborative for Health | <1 mi |
| Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Phase 3 | Takeda | <1 mi |
| Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema | Phase 2 | Sanofi | <1 mi |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Phase 2 | AstraZeneca | <1 mi |
| First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours | Phase 1/2 | AstraZeneca | <1 mi |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Phase 1/2 | Tvardi Therapeutics, Incorporated | <1 mi |
| A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study of ZW251 in Participants With Advanced Solid Tumors | Phase 1 | Zymeworks BC Inc. | <1 mi |
| Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma | Phase 1 | Shanghai Henlius Biotech | <1 mi |
| Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | Phase 2 | Allison O'Neill, MD | <1 mi |
| Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | Phase 1 | Baylor College of Medicine | <1 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | <1 mi |
| High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies | N/A | M.D. Anderson Cancer Center | <1 mi |
| Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | Phase 1/2 | 7 Hills Pharma, LLC | <1 mi |
| National Liver Cancer Screening Trial | Phase 4 | University of Texas Southwestern Medical Center | <1 mi |
| The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study | — | UMC Utrecht | <1 mi |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | Phase 2 | Genentech, Inc. | <1 mi |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Phase 1/2 | Children's Oncology Group | <1 mi |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | AstraZeneca | <1 mi |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | Phase 3 | Children's Oncology Group | <1 mi |
| Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Phase 1 | Gilead Sciences | <1 mi |
| A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function | Phase 1 | Epizyme, Inc. | <1 mi |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention | — | M.D. Anderson Cancer Center | <1 mi |
| Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) | Phase 2 | Anwaar Saeed | <1 mi |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Phase 1 | Alnylam Pharmaceuticals | <1 mi |
| A Study of MGC026 in Participants With Advanced Solid Tumors | Phase 1 | MacroGenics | <1 mi |
| A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | Phase 1/2 | ModeX Therapeutics, An OPKO Health Company | <1 mi |
| DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Phase 2 | DualityBio Inc. | <1 mi |
| A First in Human Study of PLT012 in Participants With Solid Tumor Cancers | Phase 1 | Pilatus Biosciences Inc | <1 mi |
| IDOV-Immune for Advanced Solid Tumors | Phase 1 | ViroMissile, Inc. | <1 mi |
| Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | Phase 1 | Baylor College of Medicine | <1 mi |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor | Phase 1 | Abbisko Therapeutics Co, Ltd | <1 mi |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Phase 3 | Pierre Fabre Medicament | <1 mi |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment | — | Fresenius Kabi | <1 mi |
| A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | Phase 1 | SEED Therapeutics, Inc. | <1 mi |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | Phase 1/2 | Abivax S.A. | <1 mi |
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years | Phase 4 | Guerbet | <1 mi |
| Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines | — | M.D. Anderson Cancer Center | <1 mi |
| Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | Phase 4 | The Methodist Hospital Research Institute | <1 mi |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | <1 mi |
| Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | Phase 3 | Novartis Pharmaceuticals | 7 mi |
| A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 7 mi |
| A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance | Phase 4 | AbbVie | 7 mi |
| Suprachoroidal Administration in Subjects With Metastases to the Choroid | Phase 2 | Aura Biosciences | 7 mi |
| A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes | Phase 2 | Hoffmann-La Roche | 7 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 7 mi |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | Phase 2 | AbbVie | 7 mi |
| PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study | Phase 3 | Yale University | 7 mi |
| The OBSERVE Protocol | — | Yale University | 7 mi |
| Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss | — | Boston Scientific Corporation | 7 mi |
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety | Phase 3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 mi |
| A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease | — | TScan Therapeutics, Inc. | 7 mi |
| Evaluation of Non-Invasive Tests for Metabolic Liver Disease | — | Foundation for the National Institutes of Health | 7 mi |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Phase 3 | Boehringer Ingelheim | 11 mi |
| Study of ALTO-300 in MDD | Phase 2 | Alto Neuroscience | 14 mi |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | Phase 2 | Incyte Corporation | 15 mi |
| A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Phase 2 | Daiichi Sankyo | 15 mi |
| A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder | Phase 2 | Sirtsei Pharmaceuticals, Inc. | 15 mi |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 15 mi |
| Lumason® Infusion vs. Bolus Administrations | Phase 3 | Bracco Diagnostics, Inc | 18 mi |
| To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma | Phase 2 | Stamford Pharmaceuticals, Inc. | 18 mi |
| Nipocalimab in Moderate to Severe Sjogren's Disease | Phase 3 | Janssen Research & Development, LLC | 19 mi |
| Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers | N/A | LifeNet Health | 19 mi |
| Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone | N/A | Capsicure, LLC | 19 mi |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Phase 4 | Axsome Therapeutics, Inc. | 19 mi |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | Phase 3 | Xenon Pharmaceuticals Inc. | 20 mi |
| A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | 20 mi |
| A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | Phase 3 | Merck Sharp & Dohme LLC | 22 mi |
| Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors | Phase 1/2 | Xilio Development, Inc. | 22 mi |
| Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors | Phase 1 | Riboscience, LLC. | 22 mi |
| XTX301 in Patients With Advanced Solid Tumors | Phase 1/2 | Xilio Development, Inc. | 22 mi |
| A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer | Phase 2 | AbbVie | 22 mi |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | Phase 3 | AstraZeneca | 22 mi |
| A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer | Phase 3 | Eli Lilly and Company | 22 mi |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | Phase 1 | Cullinan Therapeutics Inc. | 22 mi |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | Phase 1 | Cullinan Therapeutics Inc. | 22 mi |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Phase 3 | BriaCell Therapeutics Corporation | 22 mi |
| A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | Phase 2/3 | Pfizer | 22 mi |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection | Phase 1 | GigaGen, Inc. | 22 mi |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | Phase 3 | Boehringer Ingelheim | 23 mi |
| Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer | Phase 2 | Riboscience, LLC. | 23 mi |
| A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | Phase 3 | GlaxoSmithKline | 23 mi |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Phase 1 | Hoffmann-La Roche | 23 mi |
| A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia | Phase 1 | AVEO Pharmaceuticals, Inc. | 23 mi |
| Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy | Phase 2 | Endevica Bio | 23 mi |
| Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator | N/A | Zoll Medical Corporation | 23 mi |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | Teva Branded Pharmaceutical Products R&D, Inc. | 23 mi |
| Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | Phase 2 | AstraZeneca | 23 mi |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | Hoffmann-La Roche | 23 mi |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | 23 mi |
| A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC | Phase 3 | AstraZeneca | 23 mi |
| Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis | Phase 3 | Sun Pharmaceutical Industries Limited | 24 mi |
| A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | Phase 2 | Eli Lilly and Company | 24 mi |
| Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) | Phase 2 | Connect Biopharm LLC | 24 mi |
| A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | Phase 3 | Amgen | 24 mi |
| Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) | Phase 2 | Connect Biopharm LLC | 24 mi |
| Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Phase 2 | Genelux Corporation | 24 mi |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Phase 3 | Bristol-Myers Squibb | 24 mi |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | Phase 2 | Intra-Cellular Therapies, Inc. | 24 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) | Phase 3 | Bristol-Myers Squibb | 24 mi |
| A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | Phase 2 | Merck Sharp & Dohme LLC | 24 mi |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 27 mi |
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | Phase 2 | AbbVie | 27 mi |
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | Phase 3 | Bristol-Myers Squibb | 27 mi |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy | Phase 2 | Boehringer Ingelheim | 27 mi |
| A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | 27 mi |
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | 27 mi |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | Phase 2 | Artiva Biotherapeutics, Inc. | 27 mi |
| Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes | Phase 3 | Kailera | 28 mi |
| Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | Phase 3 | Kailera | 28 mi |
| A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) | Phase 2 | Pfizer | 28 mi |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | 28 mi |
| A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis | Phase 3 | Janssen Research & Development, LLC | 28 mi |
| A Study of SPY072 in Rheumatic Disease | Phase 2 | Spyre Therapeutics, Inc. | 28 mi |
| A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis | Phase 4 | CARE ARTHRITIS LTD. | 28 mi |
| A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer | N/A | GOG Foundation | 28 mi |
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | Phase 2 | Faeth Therapeutics | 28 mi |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | Merck Sharp & Dohme LLC | 28 mi |
| A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Loxo Oncology, Inc. | 28 mi |
| A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | Phase 2/3 | AbbVie | 28 mi |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Phase 3 | Hoffmann-La Roche | 28 mi |
| A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | Phase 3 | Aura Biosciences | 28 mi |
| A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | Phase 2 | Cybrexa Therapeutics | 28 mi |
| A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | Phase 2 | Hoffmann-La Roche | 28 mi |
| A Real-World Registry of Chronic Wounds and Ulcers | — | U.S. Wound Registry | 28 mi |
| Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders | — | Healing Hope International | 28 mi |
| The Fourth Left Atrial Appendage Occlusion Study | N/A | Hamilton Health Sciences Corporation | 28 mi |
| A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) | Phase 2 | Merck Sharp & Dohme LLC | 28 mi |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Phase 1/2 | Krystal Biotech, Inc. | 28 mi |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) | Phase 3 | Amgen | 28 mi |
| A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency | Phase 1 | Krystal Biotech, Inc. | 28 mi |
| A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | Phase 2 | Kahr Bio Australia Pty Ltd | 38 mi |
| Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors | Early 1 | Cosmo Technologies Ltd | 38 mi |
| A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | Pfizer | 38 mi |
| ACT Intervention for Type 2 Diabetes Management for Rural and Underserved Community | N/A | Sam Houston State University | 39 mi |
| Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain | Phase 1 | R3 Stem Cell | 44 mi |
| Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis | Early 1 | R3 Medical Research | 44 mi |
| Pilot Trial of Spiritual Care Interventions for Patients With Cancer | N/A | Weill Medical College of Cornell University | 47 mi |
| The Gut Microbiome and Immunotherapy Response in Solid Cancers | — | The University of Texas Medical Branch, Galveston | 47 mi |
| Correlates of CRCI and Gut Microbiome Dysbiosis; a Pilot Study | — | The University of Texas Medical Branch, Galveston | 47 mi |
| Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old) | Phase 4 | The University of Texas Medical Branch, Galveston | 47 mi |
| Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes | Phase 2 | National Cancer Institute (NCI) | 47 mi |
| Promoting Intergenerational Health in Rural Kentuckians With Diabetes (PIHRK'D) | N/A | The University of Texas Medical Branch, Galveston | 47 mi |
| Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults | N/A | Dartmouth-Hitchcock Medical Center | 47 mi |
| Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment | N/A | The University of Texas Medical Branch, Galveston | 47 mi |
| Healthy Communities Through CHW Initiatives | N/A | The University of Texas Medical Branch, Galveston | 47 mi |
| Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems | N/A | RxFunction Inc. | 47 mi |
| The Effect of Clinic Visit Audio Recordings for Self-management in Older Adults | N/A | Dartmouth-Hitchcock Medical Center | 47 mi |
| The Metabolic and Genetic Drivers of Body Composition Changes Following Weight Loss Surgery | — | The University of Texas Medical Branch, Galveston | 47 mi |
| POLARx Post Approval Study (POLARx PAS) | N/A | Boston Scientific Corporation | 47 mi |
| Viral Mucosal Reprogramming | Phase 2 | The University of Texas Medical Branch, Galveston | 47 mi |
| Primary Subtalar Arthrodesis for Calcaneal Fractures | N/A | Wake Forest University Health Sciences | 47 mi |
| Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | Phase 3 | Novartis Pharmaceuticals | 47 mi |
| A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Phase 3 | AstraZeneca | 47 mi |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Phase 2 | National Cancer Institute (NCI) | 47 mi |
| Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery | N/A | Innoblative Designs, Inc. | 47 mi |
| THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation | N/A | The University of Texas Medical Branch, Galveston | 47 mi |
| Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | Phase 1 | EMD Serono Research & Development Institute, Inc. | 47 mi |
| PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study | N/A | University of Utah | 47 mi |
| Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | National Cancer Institute (NCI) | 47 mi |
| ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) | — | Alnylam Pharmaceuticals | 47 mi |
| Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Phase 3 | Disc Medicine, Inc | 47 mi |
| Longitudinal Study of the Porphyrias | — | Icahn School of Medicine at Mount Sinai | 47 mi |